

09/377,502
A 1638
FOX PCT

#10



WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A01H 1/00, 5/00		A1	(11) International Publication Number: WO 98/32325
			(43) International Publication Date: 30 July 1998 (30.07.98)
(21) International Application Number: PCT/US98/01315		(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GR, GK, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 23 January 1998 (23.01.98)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(30) Priority Data: 60/036,483 24 January 1997 (24.01.97) US 60/065,989 14 November 1997 (14.11.97) US			
(71) Applicant: DNA PLANT TECHNOLOGY CORPORATION [US/US]; 6701 San Pablo Avenue, Oakland, CA 94608-1239 (US).			
(72) Inventors: GUTTERSON, Neal; 5169 Golden Gate Avenue, Oakland, CA 94618 (US). RALSTON, Ed; 52 Chaucer Drive, Pleasant Hill, CA 94523 (US). BURGESS, Diane; 2823 Kelsey Street, Berkeley, CA 94705 (US).			
(74) Agents: BASTIAN, Kevin, L. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US).			
(54) Title: TWO COMPONENT PLANT CELL LETHALITY METHODS AND COMPOSITIONS			
(57) Abstract <p>The present invention is directed to methods for inhibiting the growth or killing cell in an organism, particularly plants. Genetically engineered cells and which allow for killing or provision of a beneficial effect to specified cells are also provided.</p>			

10:32:50

Applicants: Wyatt Paul et al.
Serial No.: 09/377,502
Filed: August 20, 1999
Exhibit: 1

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TWO COMPONENT PLANT CELL LETHALITY METHODS AND COMPOSITIONS

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. application No. 60/036,483,
filed January 24, 1997 and U.S. Application No. 60/065,989, filed November 14, 1997.

FIELD OF THE INVENTION

The present invention relates generally to methods for preventing the
growth of specific cells in a multi-cellular eukaryote, particularly plant cells.
Recombinantly modified plant cells for expression of cytotoxic genes are also provided.

BACKGROUND OF THE INVENTION

One key objective of plant genetic engineering is to create novel traits either
through expression of an introduced gene or by silencing of an endogenous gene. One use
of targeted gene expression is the elimination of specific plant cells through the production
of an enzyme that is lethal to the cell. In order to eliminate only a specific set of cells, it
is necessary that expression of a potentially lethal function be controlled precisely such that
the cell-lethal function is expressed only in the cells targeted for elimination and in no
others.

Several different approaches have now been attempted to create novel plant
traits using a single component cell lethality system. In one-component cell lethality
systems, specific cell types are targeted for elimination using a single promoter driving
expression of a cytotoxic gene product. These approaches are initiated by the
characterization of promoters that are active in specific tissues or under specific
conditions. For example, male sterility has been demonstrated using promoters active in
tapetal tissue. A number of different promoters have been identified that are expressed in
tapetal tissue and other tissue. A further example is the use of cell lethality to create

5) disease resistance via a hypersensitive response. A number of promoters have been characterized by different workers that are induced upon pathogen infection. A further example is the attempt to create nematode resistance by killing giant cells, the specific root cells upon which cyst and root knot nematodes feed. A number of promoters have been characterized by different workers that are induced in giant cells, but again sufficient promoter specificity has been difficult to achieve.

In one example (Strittmatter *et al.*, *Bio/Technology* 13:1085-90 (1995)), the workers cite the difficulty of creating transgenic plants using a construct containing a ribonuclease coding sequence (obtained from *Bacillus amyloliquifaciens*, barnase) under the control of a promoter induced upon infection with the fungus *Phytophthora infestans*. Their solution to the difficulty was to express a protective function, barstar, under the control of a constitutive promoter that would hopefully protect non-infected cells, but allow infected cells to be killed. A further example is the attempt to create nematode resistance by killing the specific root cells upon which cyst and root knot nematodes feed, as described in WO 92/21757, WO 93/10251, WO 93/18170, WO 94/10320, and WO 94/17194. A number of promoters have been characterized by different workers that are induced in specialized nematode feeding cells, but again sufficient promoter specificity has been difficult to achieve.

In one case (WO 93/10251), the difficulty of obtaining sufficient promoter specificity is addressed through expression of a protective function in cells other than the target cells. Another example of the protective approach is described in WO 96/26283, which described the production of male sterility using the tapetal specific promoter TA29 from tobacco to program expression of barnase. As in the example above, the protective function for the barnase protein is the barstar protein, whose expression is sought in non-target tissues. Unfortunately, for many potentially useful cell-lethal functions, protective functions are not available. In order to make a protective approach work, it is necessary to identify a second promoter with the requisite "inverse" specificity.

In vertebrates similar cell lethality approaches have been reported to ablate specific cell types or tissue types as an experimental tool, or to kill cells involved in a disease state, such as HIV-infected cells or metastatic cancer cells. The principal cell lethality function chosen for cell ablation is the diphtheria toxin (DT) A chain, which adenoribosylates elongation factor EF-2, thus blocking protein synthesis. Herrera *et al.*,

Proc. Natl. Acad. Sci., USA 91:12999-13003 (1994). Because of the extreme toxicity of the DT A chain, precise expression is critical. An approach that has been taken in therapeutic situations is the specific introduction and/or expression of a thymidine kinase (tk) gene. The tk gene product is a conditional cell-lethal function, requiring the presence of a nucleoside analog such as ganciclovir for lethality. Brady *et al.*, *Proc. Natl. Acad. Sci., USA* 91:365-69 (1994) describe the use of this approach for specific ablation of human immunodeficiency virus Tat-expressing cells following introduction of a tk gene whose expression is under control of the Tat protein and treatment with ganciclovir.

10 In developing ways to kill specific subpopulations of cells within an organism, such as metastatic cancer cells in a mammal, the requirement of "twofold specificity", has been recognized. Panchal *et al.*, *Nature Biotechnol.* 14:852-56 (1996). The approach taken by Panchal *et al.* was to use immunorecognition of the surface of cancer cells as the first level of specificity, and specific protease activities of cancer cells as the second level of specificity.

15 In the case of plants, by targeting expression to cells in the tapetum, male sterile plants can be produced. The production of male sterile plants is particularly useful in producing F1 hybrids. F1 hybrid plants are used extensively in most areas of agriculture because of their improved traits, such as increased yield, disease or low temperature resistance. F1 hybrids are often produced by a manual process of
20 emasculation of the intended female of the cross, to prevent self pollination, followed by application of pollen taken from the male of the cross to the stigma of the female of the cross. The production of such hybrids is labor intensive, which contributes greatly to the increased cost of hybrid seed.

25 Several different approaches have now been attempted to use cell lethality systems in the production of male sterile lines by targeting expression of lethal protein to the tapetum. For example, WO 96/26283, describes the production of male sterility using the tapetal specific promoter TA29 from tobacco to program expression of the ribonuclease, barnase. U.S. Patent No. 5,409,823 discloses use of transactivators to control expression of gene products which disrupt formation of pollen. Since it is often
30 desirable that the male fertility be restored in either the male sterile line or the F1 hybrid, attempts have been made to produce plants in which male sterility can be made conditional. Examples of this approach include WO 93/25695 and WO 97/13401.

What is needed in the art are compositions and methods which provide selective elimination or inhibition of growth of a selected cell type in an organism, for example, in a plant. The present invention provides these and other advantages.

5

SUMMARY OF THE INVENTION

In one aspect, the present invention is directed to a plant cell. The plant cell comprises a first expression cassette comprising a first non-constitutive plant promoter operably linked to a polynucleotide encoding a first polypeptide and a second expression cassette comprising a second non-constitutive plant promoter operably linked to a
10 polynucleotide encoding a second polypeptide. At least the first or the second expression cassette is heterologous to the cell. Further, the first and second promoters have different but overlapping specificities such that the first and second polypeptides are expressed in the same cell.

In some embodiments, the presence of the first and second polypeptides in
15 the same cell impairs cellular function. In some embodiments, the first and second polypeptides each comprise a separate subsequence of a single functional polypeptide. The functional polypeptide can be a ribonuclease such as Barnase, or T1. The functional polypeptide be modified to have enhanced stability. In one embodiment, the enhanced stability barnase is bn3-2 and bn5-2. In additional embodiments of the plant cell, the first
20 polypeptide is an avirulence gene product derived from a plant pathogen and the second polypeptide is a resistance gene product associated with the avirulence gene.

For example, first polypeptide can be avr9 and the second polypeptide cfo9. The functional polypeptide can be a nuclease or colicin. In some plant cell
25 embodiments, the first or the second promoter is a tissue-specific promoter such as when each is functional in seeds or tapetal cells. In some embodiments, the first or second promoter is induced following interaction with a plant pathogen or pest.

In another aspect, the present invention relates to a plant cell comprising a first expression cassette comprising a first plant promoter operably linked to a
30 polynucleotide encoding a first polypeptide and a second expression cassette comprising a second plant promoter operably linked to a polynucleotide encoding a second polypeptide. The first and second polypeptides each comprise a separate subsequence of a single functional polypeptide.

Often, the functional polypeptide impairs cellular function. In some embodiments, the first and second promoters have different but overlapping specificities such that the first and second polypeptides are expressed in the same cell.

In another aspect, the present invention relates to a method for modifying
5 the cellular function of a plant cell. The method comprises the steps of introducing into the cell a first expression cassette comprising a first non-constitutive plant promoter operably linked to a polynucleotide encoding a first polypeptide and a second expression cassette comprising a second non-constitutive plant promoter operably linked to a
10 polynucleotide encoding a second polypeptide, wherein the first and second promoters have different but overlapping specificities such that the first and second polypeptides are expressed in the same cell. The first or the second expression cassettes can be introduced into the plant cell through a sexual cross.

In yet another aspect, the present invention relates to a method of modifying cellular function in a plant cell. The method comprises the steps of introducing into a plant
15 cell a first expression cassette comprising a first plant promoter operably linked to a polynucleotide encoding a first non-functional polypeptide and a second expression cassette comprising a second plant promoter operably linked to a polynucleotide encoding a second non-functional polypeptide, wherein the first and second polypeptides each comprise a separate subsequence of a single functional polypeptide. Often, the first and second
20 promoters have different but overlapping specificities such that the first and second polypeptides are expressed in the same cell.

In a further aspect, the present invention is directed to a method for preventing the growth of a eukaryotic cell. The method comprises the steps of introducing into the cell, a first expression cassette comprising a first tissue-specific plant promoter
25 operably linked to a polynucleotide encoding a first polypeptide and a second expression cassette comprising a second tissue-specific plant promoter operably linked to a polynucleotide encoding a second polypeptide, wherein the first and second promoters are functional in the cell and presence of the first and second polypeptides in a cell impairs cellular function. In some embodiments the cell is a mammalian cell. The mammalian
30 cell can be in a non-human animal. Often, the first and second expression cassettes are introduced into the cell using a retroviral vector.

5
The present invention further provides plants containing a plant cell comprising a first and a second expression cassette located at the same locus on each of two homologous chromosomes. One expression cassette comprises a first plant promoter operably linked to a first polynucleotide sequence encoding a first polypeptide. A recombinase site (*e.g.*, a lox site) is present between the first promoter and the first polynucleotide sequence. A second expression cassette comprises the first plant promoter inoperably linked to the first polynucleotide sequence, wherein an intervening expression cassette is flanked by two recombinase sites and situated between the first promoter and the first polynucleotide sequence of the second expression cassette. The intervening expression cassette comprises a second plant promoter operably linked to a second polynucleotide sequence encoding a second polypeptide. The presence of the first and second polypeptides in a cell is lethal to the cell.

10
The first and second polypeptide can be selected from a number of proteins, which when present together are lethal to a cell. For instance, one polypeptide can be a transactivator protein which activates expression of the other expression cassette which encodes a polypeptide which is lethal to plant cells (*e.g.*, a ribonuclease). Alternatively, the polypeptides can be an avirulence gene product derived from a plant pathogen and a plant resistance gene product associated with the avirulence gene (*e.g.*, AVR9 and CF9).

15
The promoters in the two expression cassettes preferably provide tissue specific expression of one or both of the polypeptides. In some embodiments, the target cells are tapetal cells.

20
Methods of preparing plants of the invention are also provided. For instance, the plants can be prepared by introducing into a plant the expression cassettes described above.

25 BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows how the allelic variants of p-Mon-Avr9 or TA29-Cf9 containing sublines (A₁ and A₂) are created using the cre/lox recombinase system and their use in producing male steriles. ALS = acetolactate synthase.

30
Figure 2 shows the production of allelic variants of the invention using the cre/lox system and AVR9/CF9. ALS = acetolactate synthase.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for inhibiting the growth or killing of specified eukaryotic cells in multicellular eukaryotic organisms, particularly plants. More specifically, the present invention relates to plant cells comprising at least two expression cassettes operably linked to polynucleotides which when expressed provide a desired effect to specific tissue or cell types. The desired effect can impair cellular function or can be beneficial to the cell (e.g., resistance to plant pathogens or pests). The expression cassettes can occupy the same or different loci of chromosome homologs, or be located on different chromosomes or elsewhere as part of the genome. The present invention provides novel methods for producing plants which can utilize the multi-component system described herein, and embraces the plants so produced and methods of their use.

In contrast to one-component lethality systems in which the use of individual promoters drives expression of a cytotoxic polypeptide, the two or more component lethality/inhibitory methods of the present invention employs two or more promoters having overlapping but distinct tissue-specific expression. This system provides a greater degree of control in targeting a desired function to selected cells than one-component systems. Two or more component systems will typically be optimized by consideration of the following: 1) the desired effect should be cell autonomous; 2) the desired effect should not be dependent upon any other cellular function; 3) the desired effect should be a sensitive function of the level of the associated components.

Methods of the present invention provide means to maintain inbred lines in a hybrid system in which there is no inhibitory or lethality expressed in either inbred line. However, crossing these inbred lines yields a hybrid having the inhibitory or lethal phenotype. The present invention also provides a means to produce a lethal or inhibitory effect in a highly tissue-specific, condition-specific, or developmental stage-specific manner, using two different promoters with overlapping specificity to obtain the necessary specificity. The resulting invention has utility, for example, in creating and maintaining male sterile and female sterile plants.

Definitions

Units, prefixes, and symbols can be denoted in their SI accepted form.

Numeric ranges are inclusive of the numbers defining the range. The headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants.

As used herein "operably linked" includes reference to a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the RNA sequence which is typically transcribed into a polypeptide. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

As used herein, an "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a target cell. The expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the expression cassette portion of the expression vector includes, among other sequences, a nucleic acid to be transcribed, and a promoter.

The terms "chromosome homolog" or "homologous chromosome" refers to two or more chromosomes that can pair during meiosis. Each homologue is a duplicate of a chromosome contributed by the male or female parent. Homologous chromosomes contain the same linear sequence of genes, each gene (or allele) is present at the same locus on each homolog.

Two polynucleotide sequences (e.g., two expression cassettes of the invention) are said to be at the "same locus" if the two sequences are genetically mapped to

the same locus as determined, for instance, by frequency of crossover events between the two loci.

As used herein, "lethal" or "impairs cellular function" includes reference to polynucleotide(s) or polypeptide(s) that are cytotoxic to an extent that kills cells or inhibits cell division or differentiation. Thus, "lethal" or "impairs cellular function" includes reference either to 1) the disruption of a cell through perturbation of some function of the cell or by degradation of a component of the cell, or 2) to the prevention of continued growth of a cell through perturbation of some function of the cell or degradation of some component of the cell. By way of example, but not limitation, typical cellular functions in the context of the instant invention are protein synthesis, RNA synthesis, maintenance of osmotic competence, lipid synthesis, DNA synthesis. Typical cellular components subject to degradation in the context of the instant invention are proteins, carbohydrates, membranes, deoxyribonucleic acids, ribonucleic acids.

As used herein, "beneficial" includes reference to polynucleotide(s) or polypeptide(s) that impart a protective effect to a cell. In plants, a beneficial effect includes resistance to environmental stresses including, but not limited to, plant pathogens, pests, drought, heavy metals, and salt.

As used herein, "heterologous" is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its original form. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form. Thus, a "heterologous expression cassette" is one that comprises at least one element not endogenous to the species or sub-species in which it is introduced.

As used herein, "polynucleotide" and "nucleic acid" includes reference to both double stranded and single stranded DNA or RNA. The terms also refer to synthetically or recombinantly derived sequences essentially free of non-nucleic acid contamination. A polynucleotide can be a gene subsequence or a full length gene (cDNA or genomic). Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides, which have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly

encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with
5 mixed-base and/or deoxyinosine residues (Batzer *et al.*, *Nucleic Acid Res.* 19:5081 (1991); Ohtsuka *et al.*, *J. Biol. Chem.* 260:2605-2608 (1985); Rossolini *et al.*, *Mol. Cell. Probes* 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.

10 The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.

"Conservatively modified variants" applies to both amino acid and nucleic
15 acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the
20 codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes
25 every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

30 As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino

acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid.

Conservative substitution tables providing functionally similar amino acids are well known in the art.

5 The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 10 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

(see, e.g., Creighton, *Proteins* (1984)).

15 The term "enhanced stability" refers to a polypeptide that has been modified so that one or more of the amino acids has been changed relative to the wild type polypeptide. Such modifications provide enhanced stability to the polypeptide, either alone or in combination with another polypeptide. Enhanced stability includes, e.g., enhanced thermal stability, enhanced activity at lower concentrations, enhanced active site activity, and the like.

20 As used herein, "functional" includes reference to an activity sufficient to produce a desired effect. Thus, for example, a promoter functional in a specified cell will drive expression to the desired levels. A "functional polypeptide" will have the activity to achieve a desired result, such as cell inhibition or death. Alternatively, a functional polypeptide will provide the cell with a beneficial or therapeutic effect, such as resistance
25 to plant pests or disease. In some embodiments in which a functional polypeptide (e.g., a ribonuclease such as barnase) is produced in cells comprising 2 or more expression cassettes of the invention, an active expression cassette produces a "functional polypeptide" as defined herein. Thus reference to a particular protein or "functional polypeptide" includes the naturally occurring protein or a protein produced in a cell that
30 has the substantially the same activity as the naturally occurring protein. "Functional polypeptides" of the invention also include modified polypeptides (with amino acid

substitutions, both conservative and non-conservative) that have the same activity as a wild-type or unmodified polypeptide.

As used herein "promoter" includes reference to a region of DNA upstream from the start of transcription and involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating transcription in plant cells. Examples of promoters under developmental control include promoters that initiate transcription only in certain tissues, such as leaves, roots, fruit, seeds, tapetal tissue, anthers, stigmas, or flowers. Such promoters are referred to as "tissue specific". A "cell type" specific promoter is primarily drives expression in certain cell types in one or more organs, for example, vascular cells in roots or leaves. An "inducible" promoter is a promoter which is under environmental control. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions or the presence of light. Tissue specific, cell type specific, and inducible promoters constitute the class of "non-constitutive" promoters. A "constitutive" promoter is a promoter which is active under most environmental conditions.

Plant Compositions and Methods

The present invention has use over a broad range of types of plants, including species from the genera *Cucurbita*, *Rosa*, *Vitis*, *Juglans*, *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*, *Pelargonium*, *Panieum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Pisum*, *Phaseolus*, *Lolium*, *Oryza*, *Zea*, *Avena*, *Hordeum*, *Secale*, *Triticum*, *Sorghum* and *Datura*.

The expression cassettes of the multi-component cell lethality system of the present invention are DNA or RNA constructs which can be cloned and/or synthesized by any number of standard techniques. An expression cassette will typically comprise transcriptional and translational initiation regulatory sequences which will direct the transcription of the polynucleotide encoding a non-lethal polypeptide in the intended tissues of the transformed plant. Such nucleic acid constructs may be introduced into the

genome of the desired plant host by a variety of conventional techniques. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, e.g., Weising *et al. Ann. Rev. Genet.* 22:421-477 (1988).

5 For example, the DNA or RNA nucleic acid construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the nucleic acid constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. Alternatively, the nucleic acid constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria. *Agrobacterium tumefaciens*-mediated transformation techniques, including disarming and use of binary vectors, are well described in the scientific literature. See, e.g., Horsch *et al. Science*, 233:496-498 (1984), and Fraley *et al. Proc. Natl. Acad. Sci. USA* 80:4803 (1983).

Microinjection techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al. EMBO J.* 3:2717-2722 (1984). Electroporation techniques are described in Fromm *et al. Proc. Natl. Acad. Sci. USA* 82:5824 (1985). Ballistic transformation techniques are described in Klein *et al. Nature* 327:70-73 (1987).

The expression cassettes of the present invention can comprise a marker gene which confers a selectable phenotype on plant cells. For example, the marker may encode biocide resistance, particularly antibiotic resistance, such as resistance to kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta.

Two-component lethality

Plant cells of the present invention comprise two or more expression cassettes. When an expression cassette of the present invention is in a cell in which the promoter is functional, the promoter drives expression of the operably linked polynucleotide. Such an expression is a functional expression cassette. When the

promoters of both expression cassettes are functional in a cell two "functional transcripts" are made, at least one of which is typically translated to a "functional polypeptide". As a result, for example, cell function is disrupted such that the cell is inhibited or killed. Individually, neither of the expression cassettes is capable of causing the desired result. In some embodiments, the presence in the cell of all functional expression cassettes of the two or more component system yields an inhibitory or cytotoxic effect upon the cell. In some embodiments, the two or more (multi) component system of the invention yields a beneficial effect, e.g., resistance to a plant pathogen or pest.

In some embodiments, one of the expression cassettes is able to express its operably linked polynucleotide in the absence of the other collaborating expression cassette. The collaborating expression cassette requires the presence of the polypeptide expressed by its partner expression cassette to become functional; typically the product of this inducible expression cassette is by itself lethal or inhibitory. For example, the polypeptide may be an activator polypeptide as in the tet repressor/VP16 activator fusion as discussed in Weinmann *et al.*, *The Plant Journal*, 5(4):559-569 (1994).

Insertion at identical loci on homologous chromosomes

The two or more components of the lethality system of the present invention can be introduced randomly into the plant genome, or as alleles of each other at a single locus of a homologous pair. In some embodiments of the present invention, each of the expression cassettes are located at the same locus on each chromosome of a homologous pair. A particularly preferred means of introducing each expression cassette at the same locus employs the cre/lox recombinase system. Bayley *et al.*, *Plant Molecular Biology* 18:353-361 (1992). The cre/lox system allows the introduction of a precursor expression cassette which can subsequently be manipulated via cre recombinase to remove a subsequence of that precursor cassette. In this way alternate alleles can be made. Accordingly, the recombinase allows the formation of the two expression cassettes employed in the two-component lethality system of the present invention. Other recombinase systems include the *Saccharomyces cerevisiae* FLP/FRT, lambda att/Int, R recombinase of *Zygosaccharomyces rouxii*, and Mu Gin recombinase. Alternatively, one of the polynucleotides encoding a non-lethal peptide of the present invention could be located on a transposable element such as *Ds* from maize which could be excised by

crossing to a line carrying a transposase (*see, e.g., Carroll et al. Genetics 139:407-420 (1995)*).

In one embodiment of the invention, an expression cassette which can subsequently be manipulated via a recombinase to remove an intervening subsequence of that cassette is introduced into a plant. The intervening expression cassette is positioned between recombinase sites in the same orientation, such that the promoter of the expression cassette is inoperably linked to a coding sequence. In the presence of the appropriate recombinase enzyme the intervening expression cassette is excised from the expression cassette such that the promoter is now operably linked to the corresponding coding sequence. Alternatively, the recombinase can be used to insert an intervening expression cassette into a recombinase site in an expression cassette previously introduced into the plant. In the presence of the appropriate recombinase enzyme the intervening subsequence is inserted into the expression cassette such that the promoter is now inoperably linked to the corresponding coding sequence. Using these methods alternate functional cassettes can be introduced to a particular locus in the genome. One of the cassettes will have within it a non-functional expression cassette and will also have within it a functional intervening expression cassette. The other of the cassettes will be a functional expression cassette (without the intervening sequence).

In the invention, the intervening sequence also includes an intervening expression cassette encoding a second polypeptide. The presence of polypeptides from both expression cassettes is lethal to the cell.

In one method of making plants of the invention, an initial plant line is created which contains a non-functional expression cassette interrupted by an intervening expression cassette flanked by recombinase sites in the same orientation (*e.g., lox sites*). This initial line is then crossed with a second plant containing the appropriate recombinase (*e.g., cre*). Plants in the F1 generation will contain a functional expression. F1 plants containing a functional cassette are then selfed according to standard techniques to produce a homozygous line containing a functional expression cassette encoding the first polypeptide. The original transformant is also selfed to produce a second line in which the first expression cassette remains non-functional. The two lines are then crossed to produce plants heterozygous at the locus. Cells in which both expression cassettes are functional will be eliminated.

In another method, an initial plant line is created which contains a functional expression cassette containing a recombinase site (*e.g.*, a lox site) between the promoter and the structural gene. To create a second plant line, a plasmid containing an intervening expression cassette, and a second recombinase site (*e.g.*, a lox site) is introduced into tissue or cells (*e.g.*, protoplasts) from the initial plant along with a second plasmid encoding the appropriate recombinase (*e.g.*, cre). The second plant line is then regenerated from the transformed tissue or cells. A recombination event between the plasmid DNA containing the intervening expression cassette and the first expression cassette will result in insertion of the plasmid DNA containing the intervening expression cassette into the first expression cassette, thereby rendering the first expression cassette non-functional and thereby yielding the second expression cassette. The two lines are then crossed to produce plants containing the two cassettes at the same locus on each of the two homologous chromosomes heterozygous at the locus. Cells in which both expression cassettes are functional will be eliminated.

In these embodiments, it is desirable to use combinations of mutant lox sites to increase the relative efficiency of the insertion event or excision. Mutant lox sites (*e.g.*, lox₆₆ and lox₇₇) are described by Albert *et al.* *Plant J.* 6:649-659 (1995)),

Using a recombinase system, two alternative alleles at one locus can be created encoding each one of the polypeptides of the present invention which, when homozygous, yield alternate sublines (*e.g.*, sublines A₁ and A₂). Crossing of sublines A₁ and A₂ yield the heterozygote line, A. Since the alternate alleles of line A are at the same locus they will segregate away from each other upon crossing the line A heterozygote with a line which is absent either of these alleles, line B. The resulting hybrids will have only one functional expression cassette of the multi-component system per cell and, consequently, these cells will not yield a desired lethal or beneficial result (*e.g.*, the male sterile line A described above will be 100% male fertile).

For example, sublines A₁ and A₂, each having one expression cassette of the two-component system, can be created using a recombinase system as described above, preferably the cre/lox system. The initial transformant will have a first polynucleotide, often encoding a first polypeptide, operably linked to a first promoter and inserted in opposite orientation between a second promoter which drives expression of a second polypeptide.

Lox sites are placed in the same orientation on both sides of the second expression cassette insert. When made homozygous (via any number of standard breeding) this will yield subline A₁. The first polynucleotide in this A₁ construct is not expressed since an insert is present between the first promoter and the polynucleotide encoding the first polynucleotide.

Subline A₂ is created by crossing line A₁ to a line carrying a recombinase which recognizes the recombination sites (e.g., the lox sites) and excises the intervening sequence allowing the first promoter to drive expression of the first polynucleotide to which it is operably linked. When made homozygous by breeding methods well known to those of skill in the art, this will be used as line A₂. Hybrid line A is formed by crossing sublines A₁ and A₂ to yield a plant comprising a functional multi-component system of the present invention.

In some embodiments a tet operator-Ms polynucleotide is inserted in opposite orientation between a tapetal-specific promoter such as TA29 and the tet repressor/VP16 (Act) activator. Lox sites are placed in the same orientation on both sides of these first promoter-first polynucleotide inserts. In the homozygous subline of this construct, A₁, the regulatory protein Act) is not expressed since the tet operator-Ms gene is present between the TA29 and Act (the regulatory protein). Subline A₂, which lacks the insert as a result of cre, expresses Act, the activator of the tet operator. Crossing of A₁ to homozygous subline A₂ results in expression of Ms and results in 100% male sterile hybrids.

In other embodiments, a pMon-Avr9 gene is flanked by lox sites and inserted in opposite orientation between a tapetal-specific promoter such as TA29 and Cf9.

In this construct, only the pMon-Avr9 gene will be expressed. Another subline is created in which the insert is removed by a recombinase and the TA29 promoter drives expression of Cf9. Crossing of these two lines results in a hybrid which is male sterile due to the joint expression of Avr9 and Cf9 in tapetal cells.

Promoters

The promoters employed in the expression cassettes of the present invention can be chosen to function in identical sets of tissue types simultaneously, or at different stages of development or of the cell cycle. However, the individual promoters are

generally chosen such that they will function in multiple, different, and overlapping subsets of cells. Accordingly, the promoters of the present invention typically have "different but overlapping specificities." The overlap of these different subsets is that collection of cells where all expression cassettes of the multi-component system are present and functional. The presence in a cell of all of the complete set of functional expression cassettes of the multi-component system will result in a desired effect on the organism. Thus, for example, a single functional expression cassette within a cell yields a non-lethal/non-inhibitory phenotype. However, the presence of both functional expression cassettes in the same cell yields the inhibitory or lethal phenotype.

5
10 A very wide range of promoters can be used with the multi-component system of the present invention. Methods for identifying promoters with a particular expression pattern, in terms of, e.g., tissue type, cell type, stage of development, and/or environmental conditions, are well known in the art. A typical step in promoter isolation methods is identification of gene products that are expressed with some degree of
15 specificity in the target tissue. Amongst the range of methodologies are: differential hybridization to cDNA libraries; subtractive hybridization; differential display; differential 2-D gel electrophoresis; isolation of proteins known to be expressed with some specificity in the target tissue. Such methods are well known to those of skill in the art.

20 For the protein-based methods, it is necessary to obtain the amino acid sequence for at least a portion of the identified protein, and then to use the protein sequence as the basis for preparing a nucleic acid that can be used as a probe to identify either genomic DNA directly, or preferably, to identify a cDNA clone from a library prepared from the target tissue. Once such a cDNA clone has been identified, that sequence can be used to identify the sequence at the 5' end of the transcript of the
25 indicated gene. For differential hybridization, subtractive hybridization and differential display, the nucleic acid sequence identified as enriched in the target tissue is used to identify the sequence at the 5' end of the transcript of the indicated gene. Once such sequences are identified, starting either from protein sequences or nucleic acid sequences, any of these sequences identified as being from the gene transcript can be used to screen a
30 genomic library prepared from the target organism. Methods for identifying and confirming the transcriptional start site are well known in the art.

In the process of isolating promoters expressed under particular environmental conditions or stresses, or in specific tissues, or at particular developmental stages, a number of genes are identified that are expressed under the desired circumstances, in the desired tissue, or at the desired stage. Further analysis will reveal expression of each particular gene in one or more other tissues of the plant. If the cell lethality function is only formed upon association of two different gene products, then it is only necessary to identify two promoters with activity in the desired tissue or condition but that do not have activity in any other common tissue.

Once promoter and/or gene sequences are known, a region of suitable size is selected from the genomic DNA that is 5' to the transcriptional start, or the translational start site, and such sequences are then linked to a partial coding sequence as described above. If the transcriptional start site is used as the point of fusion, any of a number of possible 5' untranslated regions can be used in between the transcriptional start site and the partial coding sequence. If the translational start site at the 3' end of the specific promoter is used, then it is linked directly to the methionine start codon of a partial coding sequence.

To identify the promoters, the 5' portions of the clones described here are analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs upstream of the transcription start site. In plants, further upstream from the TATA box, at positions -80 to -100, there is typically a promoter element with a series of adenines surrounding the trinucleotide G (or T) N G. J. Messing *et al.*, in *Genetic Engineering in Plants*, pp. 221-227 (Kosage, Meredith and Hollaender, eds. 1983). If proper polypeptide expression is desired, a polyadenylation region should be included. The polyadenylation region can be derived from the 3' end of a natural gene, from a variety of other plant genes, or from T-DNA.

Modification of the promoter characterized as described herein can be done using any of a number of methods well known in the art. For example, specific enhancer sequences can be added to the promoter to increase the expression level or to modify the expression pattern. Further, an intron sequence can be added to the 5' untranslated region or the coding sequence of the partial coding sequence to increase the amount of the mature message that accumulates in the cytosol.

Examples of such promoters include TA29 from tobacco (Mariani *et al.*, *Nature*, 347:737-41, (1990)), 127a, 108, 92b, 101B, and 5B from tomato (Chen and Smith, *Plant Physiol.*, 101:1413 (1993), Smith *et al. Mol. Gen. Genet.* 222:9-16 (1990) Aguirre and Smith, *Plant Mol. Biol.*, 23:477-87, (1993)), *tap1* from *Antirrhinum majus* (Nacken *et al. Mol. Gen. Genet.* 229:129-136 (1991), and A6 and A9 from *Brassica* (Paul *et al.*, *Plant Mol. Biol.*, 19:611-22, (1992), Hird *et al. Plant Journal* 4:1023-1033 (1993)). Anther-specific promoters could also be used such as ones isolated by Twell *et al.* (*Mol. Gen. Genet.*, 217:240-45, (1991)). Anther-specific promoters could also be used such as ones isolated by Twell *et al.*, *Mol. Gen. Genet.* 217:240-45 (1991) or Scott *et al.*, *Plant Mol. Biol.* 17:195-207 (1991). Seed coat specific promoters, such as the pT218 promoter (Fobert *et al.*, *The Plant Journal* 6:567-77 (1994)) or the pWM403 promoter could also be used in the present invention. Tissue-specific promoters for a range of different tissues have been identified, including roots, sepals, petals, and vascular elements. In addition, promoters induced upon pathogen infection have been identified, such as the *prp-1* promoter (Strittmatter *et al.*, *Bio/Technology* 13:1085-90 (1995)). Promoters induced in specialized nematode feeding structures have been identified (disclosed in patent applications WO 92/21757, WO 93/10251, WO 93/18170, WO 94/10320, WO 94/17194).

In some embodiments the promoter in one of the expression cassettes is a promoter inducible by the gene product of the second expression cassette. In these embodiments, the gene product of the inducible expression cassette is, by itself, lethal to the plant cell. Tapetal-specific expression of genes such as ribonucleases (e.g., Barnase), or premature expression of β -1,3 glucanases in the tapetum, have been shown to produce male sterility. Examples of other lethal polypeptides and nucleic acids are set forth below. In these embodiments, the second expression cassettes may encode a repressor/activator fusion protein. These proteins use activator domains fused to prokaryotic repressor domains thus turning them into transcriptional activators (see, e.g., Brent *et al. Cell* 43:729-736 (1985) and Labow *et al. Mol. Cell. Biol.* 10:3343-3356 (1990)). The repressor domains recognize specific sequences in the target promoter while the activator domains provide transcriptional activator function. An exemplary fusion protein for this purpose is a fusion between the Tn10 encoded tet repressor and the activation domain of the *Herpes simplex* protein VP16 (Weinmann *et al. The Plant Journal* 5:559 (1994)). In these

embodiments, the promoter will be a tet artificial promoter comprising at least one tet operator and a TATA-box (as described by Weinman *et al.*).

Other operator recognition systems that can be used include lacR/O, GAL4, and 434R/O. The TnpA binding protein from maize *Spm*, when fused to an activator domain such as VP16, can be used to transactivate the *Spm* promoter (Schläppi *et al.*, *Plant Mol. Biol.* 32:717-725 (1996)). Other activator domains which can be employed in the present invention include the acid domains from Vp1, ABI3, PvAlf, HAP4, and GCN4. Non-acidic activator domains can also be used, such as proline-rich domains, serine/threonine-rich domains, and glutamine-rich domains. Transactivator polypeptides are not limited to repressor/activator fusions, but include naturally occurring transactivator polypeptides such as the transcriptional activator polypeptides expressed by geminiviruses. These include the AL2 gene product from Tomato Golden Mosaic Virus (TGMV) which transactivates expression of the TGMV coat protein and BR1 movement protein genes (Sunter *et al.*, *Virology* 232:269-280 (1997)), and the AC2 gene product of the African Cassava Mosaic Virus (ACMV) which transactivates expression of the ACMV coat protein.

Lethal and Beneficial Effects

Each expression cassette of the present invention is individually functional but the product of each cassette alone does not provide the desired effect. It takes the combination of all transcripts (typically translated into polypeptides) from the individual expression cassettes to result in the desired phenotype. Such transcripts are individually are non-functional. For example, lethal or inhibitory transcripts can provide sense or antisense suppression, or lethal or inhibitory transcripts can be translated into a prozyme which is activated upon processing by a specific protease which is the product of the other expression cassette. Prozymes can be artificially created by linking a desired "pro" region to an active enzyme through a linker containing recognition sequences of a desired protease. Examples of proteases useful in the invention include proteases from potyviruses such as the NIa proteinase from tobacco etch virus or tobacco vein mottling virus (*see, e.g., Parks and Dougherty Virology* 182:17-27 (1991)).

The expression cassettes of the present invention can also jointly provide a beneficial effect to a cell. Thus, individually each expression cassette encodes a transcript

which is non-functional or encodes a non-functional polypeptide. However, the presence of both transcripts or their encoded products in a cell (e.g., both monomers of a heterodimeric protein) provides a desired function to the cell. Thus, the present invention provides lethal as well as restorative or therapeutic benefits to desired cells.

A. Polypeptides

Polypeptides of the present invention can consist of separate functional proteins from distinct loci, or the polypeptides can be derived from overlapping or non-overlapping subsequences of a single functional protein which provides for the desired phenotype when co-expressed in a cell. Additionally polypeptides of the present invention can consist of separate monomers of a lethal dimeric protein. In some embodiments the polypeptides will be a prozyme and the specific protease which processes the prozyme and renders it inhibitory or lethal.

In some embodiments, the multi-component system of the present invention is a two-component system. The two-component (two peptide) system, in which the two components are derived from a one-component (single protein) can generally be derived from any single protein that has a cell-lethal or inhibitory function (depending only upon the protein folding constraints of the initial protein). Typically, the two peptides are from non-overlapping or minimally overlapping (e.g., 50, 35, 20, 15, 10, 5 or less) subsequences from a single inhibitory or cytotoxic protein. The peptides produced reassociate in the target cell reconstituting the function of the single peptide from which the 2 partial peptides are derived.

The secondary and tertiary structure of a host of proteins and the processes of protein folding are known to those of skill and provide the basis for designing two-component peptide systems from a single protein. The 2 peptides will relate to the starting protein as 1) unmodified peptides that comprise the entire original protein, with the addition of a methionine or the conservative replacement of an amino acid with a methionine at the point of separation of the 2 peptides; 2) modified peptides as in (1) with the additional replacement of some amino acids by other amino acids designed to enhance the stability of the peptides and reassociated peptide complex; 3) modified peptides that comprise less than the full protein *in toto*; 4) peptides that are derived from only a portion

of the original protein, where the portion of the original protein encodes a suitable function.

The design of non-functional polynucleotides or their encoded polypeptides can be achieved by a number approaches well known to the skilled artisan. In the instant invention, these polynucleotides or polypeptides, when co-expressed in a cell, can confer lethality or some other desired function. These peptide subsequences, taken together, can be related to the original peptide as comprising the total protein sequence of the original functional protein, or as comprising a portion of the total protein sequence only. To ensure that sufficient temperature stability is retained in the now dimeric active protein, it may be necessary to incorporate specific amino acid changes into the partial coding sequences. The amino acid changes can be determined by examination of the original protein and the known amino acid interactions based on the protein structure as revealed through a range of physical techniques. In addition, the amino acid changes can be determined by random mutagenesis and screening of a combinatorial library of protein products. Alternatively, the amino acid changes can be determined by completely random mutagenesis and selection, using chemical treatments, PCR-induced mutagenesis, or other similar mutagenic treatments known to those skilled in the art.

The partial coding sequences derived from the original protein coding sequences is selected to retain activity of the reconstituted protein as well as a suitable level of stability with respect to environmental perturbations such as temperature changes. Several general routes can be taken to determining effective partial coding sequences.

Examples of polypeptides include avirulence/resistance gene combinations which lead to a hypersensitive response and cell death. Examples of this system are the AVR elicitor polypeptides from *Cladosporium fulvum* and the corresponding resistance genes, Cf from *Lycopersicon* (e.g., Cf2/Avr2, Cf4/Avr4, Cf5/Avr5, and Cf9/Avr9, see, Jones *et al. Science* 266:789- 793 (1994) and Hammond-Kosack and Jones *Plant Cell* 8:1773-1791 (1996)). A preferred combination is Cf9/Avr9. A hypersensitive response is elicited in cells expressing both Avr9 and Cf9 and results in cell death. In preferred embodiments, the AVR peptide is linked to a sequence targeting it to the apoplast (see, e.g., Hammond-Kosack *et al. Proc. Natl. Acad. Sci. USA* 91:10445-10449). Other avirulence/resistance gene combinations include the tomato *Pto* gene and the *Pseudomonas syringae avrPto* avirulence gene (Martin *et al. Science* 262:1432 (1993), the RPS2 gene of

Arabidopsis thaliana confers resistance to *P. syringae* that express the *avrRpt2* avirulence gene (Bent *et al. Science* 265:1856-1860 (1994)), and the tobacco N gene and TMV replicase (Padgett *et al. Molecular Plant Microbe Interactions* 10709-715 (1997)).

Polypeptides of the present invention can also be derived from overlapping
5 or non-overlapping subsequences of a single functional protein which provides for the desired phenotype when co-expressed in a cell. Additionally polypeptides of the present invention can consist of separate monomers of a lethal dimeric protein. In some embodiments the polypeptides will be a prozyme and a protease which processes the prozyme and renders it inhibitory or lethal. For example a "pro-barnase" can be
10 constructed by linking a "pro" portion via, for example, the recognition sequence for tobacco etch virus NIa proteinase (Glu-X-X-Tyr-X-Gln▼Ser/Gly, where X=any amino acid) or tobacco vein mottling virus NIa (X-X-Val-Arg-/Lys-Phe/Thr-Gln▼Ser/Gly, where X=any amino acid).

15 i. **Partial proteolysis**

A number of proteins have been separated into distinct, resolvable domains through partial proteolysis. This is a rapid way to determine suitable coding sequences for the two non-functional polynucleotides or polypeptides of the instant invention. For example, pancreatic ribonuclease A can be cleaned by subtilisin between residues 20 and
20 21, yielding a large and a small peptide, neither of which retains any activity, as essential catalytic residues are present in each peptide fragment. When the two peptides are mixed, the small peptide binds to the larger fragment and activity is reconstituted. In another example, staphylococcal nuclease can be resolved into three peptide fragments following partial proteolysis. Proteases initially cleave an intact protein at exposed residues, often
25 ones that are part of exposed loops not involved in specific domains. Following partial proteolysis and analysis of the resulting peptide fragments by polyacrylamide gel electrophoresis to confirm that a simple digestion resulted, residual activity is evaluated. If activity is retained, the peptides are separated to determine whether neither peptide retains activity separately, and subsequently whether activity can be reconstituted upon
30 remilling. Sequencing of the amino and carboxy termini of the two (or more) fragments reveals how to engineer the partial coding sequences in the instant invention.

ii. Sequence conservation-based design

In situations where a number of sequences are available for proteins with the same function (e.g., subtilisin family proteins; colicin family proteins; ribonuclease family proteins), it is possible to identify regions that are not well conserved in all proteins. In combination with predictive analysis of secondary structure, it is possible to identify regions of the protein that are good candidates for separation into separate peptides. Such regions retain unaltered principal secondary structural features, such as alpha helices and beta-sheets. Within such regions, a number of possible replacement and coding sequence variants can be tested using an assay either for protein function *in vitro*, or for function, or for *in vivo* lethality.

iii. Structure-based design

When a three-dimensional structure is available, from x-ray crystallography, NMR spectroscopy, etc., a more precise determination of candidate regions that would comprise the partial peptides of a single functional protein is possible. Analysis of the interactions between individual amino acids in a three-dimensional structure reveals sub-domains of the original protein that have the potential to be separated and yet to bind to each other, and which sub-domains are likely to be non-functional when present separately. Additionally, analysis of these interactions reveals which amino acids, located between suitable sub-domains, are not involved in specific interactions with other amino acids in a way that would permit replacement with a methionine residue. Such an analysis is aided by additional sequence data for proteins with a high proportion of sequence relatedness to the starting protein. This provides additional evidence concerning residues that can be replaced with a methionine residue.

Exemplary polypeptides of the present invention include ribonucleases such as barnase (Mauguen *et al.*, *Nature* 297:162-64 (1982)), binase (Pavlovsky *et al.*, *FEBS Lett.* 162:167-70 (1983)), Ribonuclease T1 (Fujii *et al.*, *Biosci. Biotechnol. Biochem.* 59:1869-1874 (1995)), nucleases such as colicin E9 (Wallis *et al.*, *Eur. J. Biochem* 220:447-54 (1994)) or BamHI (Newman *et al.*, *Science* 269:656-63 (1995)), and proteases such as subtilisin BPN' (Eder *et al.*, *J. Mol. Biol.* 233:293-304) or other members of the subtilisin family. In some embodiments, these polypeptides are used to yield male sterility when co-expressed in tapetal tissue. Other polypeptides for creating cell toxicity or

inhibition include those which produce toxic substances, disrupt cell function, suppress genes required by the cell (such as by using anti-sense, sense suppression, or ribozymes), and disruption of mitochondrial function. In particularly preferred embodiments, the polypeptide is derived from a separate subsequence of a ribonuclease such as barnase. For
5 barnase, the minimal length of each polypeptide is at least 20 amino acids. Generally, the extent of overlap of barnase polypeptides will be no more than 5 amino acids.

The enzyme barnase is a well-studied cell lethality function that has already been shown to be cell-autonomous, independent of other cellular functions, and very sensitive. Barnase expression has been shown to inhibit cell growth and development in
10 specific plant tissues. The mature barnase protein consists of a 110 amino acid polypeptide. It has been shown in *in vitro* studies that amino acid 37 of the mature protein can be converted from a valine to a methionine with good retention of ribonuclease activity. Sancho & Fersht, *J. Mol. Biol.* 224:741-47 (1992). It has also been shown that cyanogen bromide treatment cleaves the protein into a 36 amino acid peptide and a 74
15 amino acid peptide and that neither peptide retains any activity. Further, at least 30% of normal activity is reconstituted when the two peptides are mixed *in vitro*. Sancho & Fersht, *supra*.

A particularly preferred embodiment is to produce the following two partial barnase coding subsequences via PCR amplification using a barnase gene as
20 template and 1) primers designed to introduce a methionine codon at position 1 of the mature protein coding sequence and a stop codon after position 36 of the mature protein sequence, and 2) primers designed to introduce a methionine codon at position 37 of the mature protein coding sequence while leaving the end of the mature protein coding sequence intact. The two partial coding sequences can then be manipulated further to
25 produce expression cassettes, using, for example, a promoter, a 5' untranslated region, a 3' untranslated region, and a polyadenylation signal. The two expression cassettes can be designed to create two-component lethality systems that could be used to create a range of useful traits. Another exemplary two-component polypeptide system is the use of the Avr9 elicitor polypeptide from *Cladosporium fulvum* and the corresponding resistance
30 gene, Cf9 from *Lycopersicon esculentum*. A hypersensitive response is elicited in cells expressing both Avr9 and Cf9 resulting in cell death.

Means to assay for eukaryotic cell cytotoxicity or inhibition produced by two peptide fragments of a single protein are well known in the art. For example, to determine whether the partial peptides designed as indicated above can be expressed separately without activity, but can be expressed together to give activity, enzymatic activity can be assayed directly on cell extracts containing the expressed peptides or in purified preparations of the peptides. Further, eukaryotic cell cytotoxicity or inhibition can be assayed using a range of indicators for cell function. In one preferred method, the expression cassettes can be introduced to cells along with an expression cassette that produces an easily assayed function, such as the beta-glucuronidase protein (Jefferson *et al.*, *EMBO J.* 6:3901-3907 (1987)) or firefly luciferase (De Wet *et al.*, *Mol. Cell. Biol.* 7:725-37 (1987)). If expression of the expression cassettes together is cytotoxic, then the amount of the reporter activity detected will be reduced compared with the activity detected when an expression cassette is introduced separately into a eukaryotic cell. Additionally, for example, two peptides derived from non-overlapping or minimally overlapping subsequences from a single inhibitory or cytotoxic protein such as a ribonuclease can be assayed for ribonucleolytic activity *in vitro*.

The peptides of the invention may also be modified according to standard methodology to produce polypeptides with, either separately or in combination, e.g., enhanced thermal stability, enhanced subunit association, enhanced activity at lower concentrations and the like. These peptide can also be modified to produce conservatively modified variants. The modification of the polypeptides can be achieved, e.g., by techniques known to those skilled in the art such as random or site-specific mutagenesis of the nucleic acids that encode the polypeptides. Using such methods of mutagenesis, genetically modified peptides are then assayed for reconstitution of activity *in vivo*. Activity at lower concentrations or at higher temperatures is measured by comparing the genetically modified and the original peptides.

For example, the two barnase components described above are modified separately in a way that has been shown to enhance stability of the intact barnase protein (see Example 9). The modifications selected are based on the work of Serrano *et al.*, *J. Mol. Biol.* 233:305-12 (1993), who compared the thermodynamic stability of barnase with a related protein, binase, obtained from *Bacillus intermedius*. Binase has the same amino acid sequence as barnase at all but 18 of the 110 amino acid positions. Serrano *et al.*

replaced each of the barnase amino acids with a different amino acid at positions in which the proteins differed, and measured the change in thermodynamic stability induced by the amino acid change. Enzyme activity was also measured for a subset of the mutagenized barnase forms. In this way, specific amino acid changes that enhanced stability, but had little effect on enzyme activity were identified. In particular, for the amino-terminal peptide, the glutamine at position 15 of the mature barnase protein was replaced by isoleucine, and the threonine at position 16 was replaced by arginine; for the carboxy-terminal peptide, the glycine at position 65 was replaced with a serine, and the lysine at position 108 was replaced with an arginine. These changes lead to improved function when the two modified peptides are expressed in place of the original peptides. These specific changes exemplify the type of amino acid changes that are possible; those experienced in the art will recognize that other such amino acid replacements can lead to enhanced function of the two-component system. Such changes could be ones that enhance the overall activity (V_{max}) of the dimeric enzyme rather than the stability of the dimeric enzyme.

B. Transcripts

In addition to polypeptides, the transcription products of number of DNA constructs can be used to suppress expression of endogenous plant genes and yield a beneficial or lethal result to the cell. These include cassettes which provide sense or antisense suppression, or ribozymes which, in combination with a second expression cassette, inhibit or kill the cell. Anti-sense RNA inhibition of gene expression has been shown; see, e.g., Sheehy *et al.*, *Proc. Nat. Acad. Sci. USA* 85:8805-8809 (1988), and Hiatt *et al.*, U.S. Patent No. 4,801,340. For examples of the use of sense suppression to modulate expression of endogenous genes see, Napoli *et al.*, *The Plant Cell* 2:279-289 (1990), and U.S. Patent No. 5,034,323.

Catalytic RNA molecules or ribozymes can also be used to inhibit gene expression. For example, in some embodiments a beneficial or lethal ribozyme can be transcribed upon induction by a polypeptide expressed from a second expression cassette (e.g., tet repressor/VP16 activator fusion polypeptide). It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In

carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. A general design and use of target RNA-specific ribozymes is described in Haseloff *et al. Nature*, 334:585-591 (1988).

For antisense suppression or sense suppression, the introduced sequence also need not be full length relative to either the primary transcription product or fully processed mRNA. Generally, higher homology can be used to compensate for the use of a shorter sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and homology of non-coding segments may be equally effective. Normally, a sequence of between about 30 or 40 nucleotides and about 2000 nucleotides should be used, though a sequence of at least about 100 nucleotides is preferred, a sequence of at least about 200 nucleotides is more preferred, and a sequence of at least about 500 nucleotides is especially preferred.

C. Regeneration

Transformed plant cells which are derived by any number of transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired expression cassette. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the polynucleotide encoding a desired polypeptide. Plant regeneration from cultured protoplasts is described in Evans *et al.*, *Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176 (1983); and Binding, *Regeneration of Plants, Plant Protoplasts*, pp. 21-73 (1985). Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al.*, *Ann. Rev. of Plant Phys.* 38:467-486 (1987).

In some embodiments of the present invention, the expression cassettes encoding each component of the two or more component system are either introduced into a single cell by cotransformation of cells with each of the two expression cassettes, or by sequential transformation of cells with the two expression cassettes. When two promoters

with overlapping specificity are used, cell inhibition or lethality will result in only the target tissue in which both promoters are sufficiently active.

In other embodiments the expression cassettes are introduced into different cells by transformation. Whole organisms are regenerated from the separated transformed cells, and then a hybrid organism is produced by crossing the individual organisms. In this way, the original whole organisms, each carrying a single expression cassette show no cell inhibition or lethality. However, the hybrid organism resulting from the cross will have both expression cassettes in the same cell, and will express cell inhibitory function or lethality in a manner dependent upon the expression patterns of the chosen promoters.

One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

D. Target Cell Types

As the present invention can be used to eliminate particular cells or tissue types, a number of desired traits can thus be introduced into a plant. For example, in order to produce seedless fruit of a seed propagated crop, inbred lines are made, each comprising one of the two expression cassettes whose joint expression leads to inhibition or death of the cell. For example, each expression cassette can express a non-lethal polypeptide from a seed-specific promoter. When the inbred lines are crossed, the resulting hybrid, which would be used in commercial production of a seedless fruit, carries both components that combine to block seed development in the fruit of the hybrid plant. Because the inbred lines do not carry a functional lethality gene, each line can be maintained in a homozygous condition for one of the expression cassettes.

To produce male sterility, each of the two polynucleotides is operably linked to a promoter functional in tapetal cells or pollen cells, either using the same promoter with each polynucleotide or different promoters. Inbred lines are maintained, each comprising one of the polynucleotides in homozygous condition. When the inbred lines are crossed, the resulting hybrid carries both partial genes and is male-sterile. If the two inbreds are the same line, except for the partial barnase polypeptide, then the resulting "hybrid" is a male-sterile inbred that can be used in a hybrid breeding strategy.

To produce female sterility, each of the polynucleotide sequences is operably linked with a promoter expressed in stigmatic tissues, tissues of the transmitting tract, ovule tissues, or other tissues essential for female fertility. Inbred lines are maintained, each comprising one of the two polynucleotides in homozygous condition. When the inbred lines are crossed, the resulting hybrid carries both polynucleotides and is female-sterile. If the two inbreds are the same line, except for the partial barnase gene, then the resulting "hybrid" is a female-sterile inbred that can be used in a hybrid breeding strategy.

Disease resistance in plants can be mediated by a hypersensitive response in which cells infected by a pathogen are killed to prevent further spread of the pathogen. Using promoters induced by pathogen attack and a two-component system of the present invention, a synthetic hypersensitive response can be created. For example, tolerance to root knot or cyst nematodes can be mediated by eliminating the giant cells or specialized feeder cells these pests require for continued growth and multiplication in plant roots. Using promoters induced in the giant cells or specialized feeder cells in combination with a two-component system of the present invention, these specialized root cells can be eliminated.

Hybrid seeds comprising both expression cassettes of the multi-component system are typically produced in a maintainer field using sub-lines A₁ and A₂. These sublines comprise one or the other of the two expression cassettes of the two-component system which when functional in the same cell lead to cell inhibition or cell death. Both sublines A₁ and A₂ are fertile since each carries one expression cassette of the two-component system of the invention. Upon crossing to produce line A, cell death or inhibition is initiated in the cells where both expression cassettes are functional. In some embodiments, one subline will comprise an expression cassette comprising a polynucleotide from the *Cladosporium fulvum* Avr9 avirulence gene operably linked to a tapetal-specific promoter such as pMon. In the other subline the tomato Cf9 gene (the corresponding tomato resistance gene) is operably linked to a second tapetal-specific promoter, TA29. Both sublines are male fertile since the Avr9 and Cf9 polypeptides individually do not confer cell death. However, when these sublines are crossed they yield a line in which a hypersensitive response is initiated in the tapetum resulting in cell death. Hominid-Kosack *et al.*, *PNAS* 91:10445-10449 (1994); Jones *et al.*, *Science* 266:789-793

(1994). Tapetal cell death will confer male-sterility without adversely affecting other organs. In the hybrid seed production field, the male sterile line A can be crossed to any line B to produce hybrid seeds.

In some embodiments, one subline has a dominant male sterile gene (Ms) with an artificial promoter comprising at least one tet operator and a TATA-box. In this condition the male sterile gene is not transcribed and the subline is male fertile. The corresponding subline has a tapetal-specific promoter driving the expression of a chimeric transcriptional activator. Preferably, this chimeric transcriptional activator will be Act. Weinmann *et al.*, *The Plant Journal* 5(4):559-569 (1994). The line produced from crossing the sublines will be male sterile since it contains both the transcriptional activator (Act), which is expressed specifically in the tapetum, and the tet operator-Ms gene. Tapetal-specific expression of Ms genes such as ribonucleases (e.g., Barnase), or premature expression of β -1,3 glucanases in the tapetum, have been shown to produce male sterility. In the hybrid seed production field, the male sterile line A can be crossed to any line B to produce hybrid seeds.

Mammalian Cellular Transfection and Gene Therapy

The present invention further provides packageable DNA or RNA (nucleic acid) constructs for a multi-component lethality or inhibitory system as described more fully above. The various constructs employed in gene therapy methods can be had by reference to the compositions and methods described earlier. Thus the constructs of the invention can be used to target specific mammalian cells. The packageable nucleic acid constructs allow for the transfection of eukaryotic cells *in vivo* or *ex vivo*. Generally, the eukaryotic cells are mammalian hosts, such as mice, rodents, primates, and humans. The packageable nucleic acids of the invention can be inserted into any of a number of well known vectors for the transfection of target cells and organisms as described below. Cells are transfected with a expression cassette comprising a polynucleotide operably linked to a promoter functional in the cell or in a cell of a later developmental stage. Cells transfected all of the functional expression cassettes of the multi-component lethality system will inhibit cell growth (i.e., the cell doesn't enter the cell cycle) or kill the cell. However, those of skill in the art will recognize that the multi-component system of the present invention can be modified to provide a therapeutic effect upon transfection with all

functional expression cassettes of the multi-component system; such embodiments can employ any polypeptide which produces a desirable effect.

Preferred embodiments of the present invention is targeted killing of cancerous cells. A cell capable of causing cancerous growth in a mammal is altered in multiple ways via mutation from a mammalian cell that is not capable of causing cancerous growth. It is known in the art that defects occur in the control of cell growth control networks, in the control of telomere length and in the control of contact-mediated cell growth inhibition. Although there are common themes and mechanisms underlying causation of specific cancers, a wide range of genes have been identified as oncogenic when their expression is altered or their function is altered. Certain genes are often expressed in cancerous cells which are normally not expressed in the mature cells of an intact organism. The promoters of such genes can be used in the instant invention to create a two-component system that will form a lethal function in a cancerous cell, but not in a cell under normal controls for the cell cycle, contact inhibition and telomere formation. Typical promoters would be selected from a group that includes, but is not limited to, a telomerase promoter, or a promoter under the control of myc genes. The polynucleotides of the two-component system can be delivered to cancerous cells via disarmed human viruses, liposome fusion, or other method.

The term "transfected" includes reference to the introduction of a nucleic acid into a eukaryotic cell where the nucleic acid can be incorporated into the genome of the cell (i.e., chromosome, plasmid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA). The nucleic acids are transfected into cells, *ex vivo* or *in vivo*, through the interaction of the vector and the target cell. Vectors which target distinct cell types are known in the art. For a review of gene therapy procedures, see Anderson, *Science* 256:808-813 (1992); Nabel & Felgner, *TIBTECH* 11:211-217 (1993); Mitani & Caskey, *TIBTECH* 11:162-166 (1993); Mulligan, *Science* 926-932 (1993); Dillon, *TIBTECH* 11:167-175 (1993); Miller, *Nature* 357:455-460 (1992); Van Brunt, *Biotechnology* 6(10):1149-1154 (1988); Vigne, *Restorative Neurology and Neuroscience* 8:35-36 (1995); Kremer & Perricaudet, *British Medical Bulletin* 51(1):31-44 (1995); Haddada *et al.*, in *Current Topics in Microbiology and Immunology* (Doerfler and Böhm eds., 1995); and Yu *et al.*, *Gene Therapy* 1:13-26 (1994).

Delivery of the gene or genetic material into the cell is the first critical step in gene therapy treatment of disease. A variety of methods for delivering and expressing a nucleic acid within a mammalian cell are known to those of ordinary skill in the art. Such methods include, for example liposome-based gene delivery (WO 93/24640; Mannino Gould-Fogerite, *BioTechniques* 6(7):682-691 (1988); U.S. Pat. No. 5,279,833; WO 91/06309; Felgner *et al.*, *Proc. Natl. Acad. Sci. USA* 84:7413-7414 (1987); and Budker *et al.*, *Nature Biotechnology*, 14(6):760-764 (1996)). Other methods known to the skilled artisan include electroporation (U.S. Pat. Nos. 5,545,130, 4,970,154, 5,098,843, and 5,128,257), direct gene transfer, cell fusion, precipitation methods, particle bombardment, and receptor-mediated uptake (U.S. Pat. Nos. 5,547,932, 5,525,503, 5,547,932, and 5,460,831). *See also*, U.S. Pat. No. 5,399,346.

Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immuno deficiency virus (SIV), human immuno deficiency virus (HIV), and combinations thereof. *See, e.g.*, Buchscher *et al.*, *J. Virol.* 66(5):2731-2739 (1992); Johann *et al.*, *J. Virol.* 66(5):1635-1640 (1992); Sommerfelt *et al.*, *Viol.* 176:58-59 (1990); Wilson *et al.*, *J. Virol.* 63:2374-2378 (1989); Miller *et al.*, *J. Virol.* 65:2220-2224 (1991); PCT/US94/05700, and Rosenberg & Fauci, in *Fundamental Immunology, Third Edition* (Paul ed., 1993) and the references cited therein, and Yu *et al.*, *Gene Therapy* (1994) *supra*.

AAV-based vectors are also used to transduce cells with target nucleic acids, e.g., in the *in vitro* production of nucleic acids and polypeptides, and in *vivo* and *ex vivo* gene therapy procedures. *See*, West *et al.*, *Virology* 160:38-47 (1987); U.S. Patent No. 4,797,368; WO 93/24641; Kotin, *Human Gene Therapy* 5:793-801 (1994); Muzyczka, *J. Clin. Invest.* 94:1351 (1994) and Samulski (*supra*) for an overview of AAV vectors. Construction of recombinant AAV vectors are described in a number of publications, including Lebkowski, U.S. Pat. No. 5,173,414; Tratschin *et al.*, *Mol. Cell. Biol.* 5(11):3251-3260 (1985); Tratschin *et al.*, *Mol. Cell. Biol.* 4:2072-2081 (1984); Hermonat & Muzyczka, *Proc. Natl. Acad. Sci. USA* 81:6466-6470 (1984); and Samulski *et al.*, *J. Virol.* 63:03822-3828 (1989). Cell lines that can be transfected by rAAV include those described in Lebkowski *et al.*, *Mol. Cell. Biol.* 8:3988-3996 (1988).

A. *Ex vivo* Transfection of Cells

Ex vivo cell transfection for diagnostics, research, or for gene therapy (e.g., via re-infusion of the transfected cells into the host organism) is well known to those of skill in the art. In a preferred embodiment, cells are isolated from the subject organism, transfected with an expression cassette of the present invention (gene or cDNA), and re-infused back into the subject organism (e.g., patient). Various cell types suitable for *ex vivo* transfection are well known to those of skill in the art (see, e.g., Freshney *et al.*, *Culture of Animal Cells, A Manual of Basic Technique*, third edition (1994)) and the references cited therein for a discussion of how to isolate and culture cells from patients).

In one particularly preferred embodiment, stem cells are used in *ex-vivo* procedures for cell transfection and gene therapy. The advantage to using stem cells is that they can be differentiated into other cell types *in vitro*, or can be introduced into a mammal (such as the donor of the cells) where they will engraft in the bone marrow. Methods for differentiating CD34⁺ cells *in vitro* into clinically important immune cell types using cytokines such as GM-CSF, IFN- γ and TNF- α are known (see, Inaba *et al.*, *J. Exp. Med.* 176:1693-1702 (1992)).

In mice, stem cells are isolated from bone marrow cells by panning the bone marrow cells with antibodies which bind unwanted cells, such as CD4⁺ and CD8⁺ (T cells), CD45⁺ (panB cells), GR-1 (granulocytes), and Ia^d (differentiated antigen presenting cells). For an example of this protocol see, Inaba *et al.*, *J. Exp. Med.* 176:1693-1702 (1992). Human hematopoietic progenitor and stem cells are characterized by the presence of a CD34 surface membrane antigen. This antigen is used for purification, e.g., on affinity columns which bind CD34. See, Ho *et al.*, *Stem Cells* 13 (suppl. 3):100-105 (1995). See also, Brenner, *Journal of Hematotherapy* 2:7-17 (1993). In another embodiment, hematopoietic stem cells are isolated from fetal cord blood. Yu *et al.*, *Proc. Natl. Acad. Sci. USA* 92:699-703 (1995) describe a preferred method of transducing CD34⁺ cells from human fetal cord blood using retroviral vectors.

B. *In vivo* Transfection

Vectors (e.g., retroviruses, adenoviruses, liposomes, etc.) containing therapeutic nucleic acids can be administered directly to the organism for transduction of cells *in vivo*. Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells. The packaged nucleic acids are administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Suitable methods of administering such packaged nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention.

Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, tragacanth, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.

The packaged nucleic acids, alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Suitable formulations for rectal administration include, for example, suppositories, which consist of the packaged nucleic acid with a suppository base. Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of
5 a combination of the packaged nucleic acid with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.

Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection
10 solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally,
15 intravesically or intrathecally. Parenteral administration and intravenous administration are the preferred methods of administration. The formulations of packaged nucleic acid can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.

Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Cells transduced by the packaged
20 nucleic acid as described above in the context of *ex vivo* therapy can also be administered intravenously or parenterally as described above.

The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The dose will be determined by the efficacy of the particular vector employed and the
25 condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, or transduced cell type in a particular patient.

In determining the effective amount of the vector to be administered, the
30 physician evaluates circulating plasma levels of the vector, vector toxicities, progression of the disease, and the production of anti-vector antibodies. In general, the dose equivalent of a naked nucleic acid from a vector is from about 1 μg to 100 μg for a typical 70

kilogram patient, and doses of vectors which include a retroviral particle are calculated to yield an equivalent amount of therapeutic nucleic acid.

For administration, inhibitors and transduced cells of the present invention can be administered at a rate determined by the LD-50 of the transduced cell type, and the side-effects of the cell type at various concentrations, as applied to the mass and overall health of the patient. Administration can be accomplished via single or divided doses.

Transduced cells are prepared for reinfusion according to established methods. See, Abrahamsen *et al.*, *J. Clin. Apheresis*, 6:48-53 (1991); Carter *et al.*, *J. Clin. Apheresis* 4:113-117 (1988); Aebersold *et al.*, *J. Immunol. Meth.* 112:1-7 (1988); Muul *et al.*, *J. Immunol. Methods* 101:171-181 (1987) and Carter *et al.*, *Transfusion* 27:362-365 (1987). After a period of about 2-4 weeks in culture, the cells should number between 1×10^8 and 1×10^{12} . In this regard, the growth characteristics of cells vary from patient to patient and from cell type to cell type. About 72 hours prior to reinfusion of the transduced cells, an aliquot is taken for analysis of phenotype, and percentage of cells expressing the therapeutic agent.

Treatment of Non-Mammalian Organisms

While the two or more component lethality system of the present invention is preferably employed with multicellular eukaryotic organisms such as a mammal or plant, it is also applicable to any organism, as cell inhibitory or lethality functions (e.g., ribonucleases, deoxyribonucleases, proteases, toxins) are known that effect all types of cells. The principles of protein structure and protein folding apply universally in living cells, and thus multi-component systems will function in cells of all types. In addition, a range of promoters with various expression patterns are known in the art for prokaryotic and non-plant eukaryotic cells. The combination of specifically expressed promoters with a two-component system is therefore general.

Accordingly, for example, a two-component lethality system can also be applied to prokaryotic organisms. When it is desirable to kill or inhibit the growth of bacterial cells growing within a mammalian organism, a two or more component system can be delivered to the bacterial cells specifically using specialized bacteriophage. In this case, a single promoter that is highly expressed in the target bacterial cell but without activity in the host organism or other beneficial bacterial cells, can be used with each

partial coding sequence, and the two genes delivered to the target bacterial cells in the genome of a specialized bacteriophage. As will be clear to the skilled artisan, the system can be expanded to utilize greater than two components.

Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Example 1

Example 1 describes the synthesis of partial barnase genes using a constitutive promoter.

The complete barnase coding sequence, from *B. amyloliquifaciens*, is available from GenBank under accession number M14442. Paddon & Hartley, *Gene* 40:231-239 (1986); Paddon *et al.*, *J. Bacteriol.* 171:1185-1187 (1989). Pro I barnase is cleaved to form pro II barnase (positions 391-735) after which it is cleaved again to form the mature peptide consisting of 110 amino acids. To produce two coding sequences that would encode completely non-functional peptides which would combine to give functional barnase, two pairs of PCR primers were synthesized. PCR amplifications were done according to manufacturer's recommended conditions, using Taq DNA polymerase, each pair of primers separately, and chromosomal DNA isolated from *Bacillus amyloliquifaciens* strain ATCC #23842. Bacterial DNA was isolated using standard methods.

The resulting fragments comprising the 5' partial coding sequence (bn5) and the 3' partial coding sequence (bn3), synthesized to have an NcoI site at the 5' end and an XbaI site at the 3' end of each fragment were gel purified. After digestions with NcoI and XbaI, each fragment was cloned into plasmid pNG5104, with the coding sequence of the β -glucuronidase (*uidA*) gene removed by NcoI-XbaI digestion and gel purification of the resulting large fragment. The resulting genes have each partial coding sequence operably linked to the SpMas promoter (Gelving *et al.*, 1995) and to the 3' polyadenylation region of the octopine synthase gene. The size of the inserted fragments was verified by gel electrophoresis, and at least two clones for each of the 5' genes (SpMas-bn5) and the 3' genes (SpMas-bn3) was selected for sequence analysis. The sequences were confirmed for

each of the genes, and the resulting plasmids were designated pER4013 (SpMas-bn5) and pER4022 (SpMas-bn3). The bn5 coding sequence encodes a peptide with a methionine added prior to the amino-terminal alanine of the mature barnase protein, and with a carboxy-terminal tryptophan (mature protein position 35). The bn3 coding sequence
5 encodes a peptide with the initiation methionine in place of the valine of the barnase mature protein position 36 and with the correct carboxy-terminal arginine (mature protein position 110).

Example 2

10 Example 2 describes biolistics assay for the reconstitution of a lethal function in plant cells.

Reconstitution of cell lethality was assayed by bombarding plant leaves with a mixture of pER4013 and pER4022 phagemid DNAs, along with DNA of phagemid pLVC320, which comprises a SpMas-LUC chimeric gene. As controls, pER4013 and
15 pLVC320 were delivered biolistically, and pER4022 and pLVC320 were delivered biolistically. The plasmid DNA's were prepared as single stranded, circular molecules using the M13 origin of replications in these phagemids. After determining DNA concentration by spectrophotometry, the concentration of each plasmid was adjusted to 400 $\mu\text{g}/\mu\text{l}$ in 10 mM Tris-1 mM EDTA, pH 8.0.

20 The plasmid DNA's were mixed according to standard methods and coated onto tungsten particles by mixing 80 μl of each DNA mixture with 40 μl of M17 tungsten particles (100 mg/ml in sterile water), 40 μl of 100 mM spermidine, and 100 μl of 2.5 M CaCl_2 in rapid succession. After mixing by vortexing, the particles were allowed to remain on ice for 5 min, after which the particles were collected by centrifugation in a
25 microcentrifuge for 20 sec. The supernate was removed, and the particles suspended in 100 μl of 70% ethanol.

Bombardment was performed using a device based on the Particle Inflow Gun of Finer and his colleagues. Sterile tomato leaf disks, prepared with a no. 4 cork borer and placed on sterile GF/A filter disks on Murashige and Skoog medium without any
30 plant hormones, were bombarded with 6 μl of a particle prep. The particle prep was pipetted onto the surface of the bottom half of a swinney filter unit. This was then attached to the upper half of a swinney filter unit that was attached to the Helium line at

the top of the biolistic chamber. Using a pressure of 200 psi in a Helium tank, the prechamber was loaded with Helium. After drawing a pressure of 29 inches Hg in the biolistics chamber, the Helium gas in the prechamber was released, firing the particles onto the surface of the agar in a petri plate located 12 cm from the swinney unit. Leaf disks were incubated 16 hours at 22°C prior to performing luciferase assays.

Luciferase assays were performed according to Promega, using S-adenosyl-methionine (SAM) as the energy source to prolong the burst of photon release. Plant leaf extracts were prepared in Cell Lysis Buffer, and then stored on ice. The assay tubes with 40 µl of assay solution including luciferin and SAM were preincubated at room temperature for 2 min. to 5 min. before initiating the reaction by addition of 10 µl of extract. After mixing, tubes were immediately transferred to Beckman scintillation counter LS6800, and light emission detected using the single photon counting program (special program number 6). Light emission is determined as photons (or counts) per minute (cpm), after subtracting background determined using 10 µL extract buffer in the reaction.

The luciferase assay results in Table 1 are reported as cpm/leaf disk. The combination of SpMas-bn5 with SpMas-bn3 results in a 84% reduction in luciferase activity compared with SpMas-bn5 alone and a reduction of 71% compared with SpMas-bn3 alone. This indicates reconstitution of cell lethal function by expression of the separate bn5 and bn3 peptides in the same cells. Similar results are reported in Tables 2-4.

Table 1. Luciferase activity recorded as cpm/leaf disk as described in example 2. Each construct introduced biolistically was introduced along with a luciferase reporter construct.

Gene construct	bn5 alone	bn3 alone	bn3 + bn5
shot 1	454,355	1,563,355	281,355
shot 2	176,555	561,355	120,155
shot 3	1,147,355	145,655	288,855
shot 4	686,155	1,169,355	52,155
shot 5	1,146,355	377,355	66,355
shot 6	500,355	1,294,355	132,355
shot 7	4,035,355	239,355	124,355
shot 8	1,274,355	608,355	257,355
average	1,177,605	744,893	165,368

Table 2. Luciferase activity recorded as cpm/leaf disk and as the average for 8 leaf disks. Each construct introduced biolistically was introduced along with a luciferase reporter construct as described in example 2. Samples not measured for technical reasons are reported as "lost".

Gene construct	bn5 alone	bn3 alone	bn3 + bn5
shot 1	888,225	296,695	21,235
shot 2	322,375	301,855	47,105
shot 3	754,275	597,965	40,745
shot 4	378,795	313,415	121,145
shot 5	lost	1,353,735	250,905
shot 6	652,065	3,120,605	463,765
shot 7	232,505	521,875	285,625
shot 8	431,625	398,445	390,765
average	522,838	863,074	202,661

Table 3. Luciferase activity recorded as cpm/leaf disk and as the average for 8 leaf disks. Each construct introduced biolistically was introduced along with a luciferase reporter construct as described in example 2.

Gene construct	bn5 alone	bn3 alone	bn3 + bn5
shot 1	597,940	363,740	203,760
shot 2	2,446,650	503,250	408,980
shot 3	278,710	2,209,780	944,780
shot 4	575,950	1,012,100	115,940
shot 5	708,800	7,888,740	44,530
shot 6	890,410	7,569,830	230,250
shot 7	1,015,610	1,207,308	153,570
shot 8	279,350	2,612,020	723,220
average	849,178	2,920,855	353,129

Table 4. Luciferase activity recorded as cpm/leaf disk and as the average for 8 leaf disks. Each construct introduced biolistically was introduced along with a luciferase reporter construct as described in example 2. Samples not measured for technical reasons are reported as "lost".

Gene construct	bn5 alone	bn3 alone	bn3 + bn5
shot 1	lost	38,375	9,605
shot 2	157,915	849,235	103,795
shot 3	274,385	552,715	165,205
shot 4	103,725	462,695	141,635
shot 5	247,325	202,525	215,535
shot 6	1,475,195	155,895	77,775
shot 7	1,550,975	156,225	439,265
shot 8	3,023,765	1,133,925	665,155
average	976,184	4,439,49	227,246

Example 3

Example 3 describes tobacco lines expressing an amino-terminal barnase partial peptide and a carboxy-terminal barnase partial peptide under control of a strong constitutive promoter.

5 The SpMas-bn5 gene in pER4013 is recloned as a PvuII fragment into the SmaI site of T-DNA vector pWTT2200, which has an nptII gene as the selectable marker to confer resistance to kanamycin or G418. The SpMas-bn3 gene in pER4022 is recloned as a PvuII fragment into the SmaI site of T-DNA vector pNG5185, which has an ALS gene as the selectable marker to confer resistance to chlorsulfuron.

10 Each construct, along with vector only controls, is introduced separately into *Nicotiana tabacum* cultivar petite Havana using standard leaf disk transformation methods. Several independent transgenic individuals carrying the SpMas-bn5 and SpMas-bn3 transgenes are assayed for expression by northern analysis. Three independent transgenic individuals from each class are selected as high expressers, and three of each control transformant class are also selected. Crosses are done between 1) SpMas-bn5 transgenic plants and pNG5185 transgenic plants, 2) SpMas-bn3 transgenic plants and pWTT2200 transgenic plants, and 3) SpMas-bn5 and SpMas-bn3 transgenic plants. Only in the third set of crosses would a functional cell lethal function be expressed in those cells which carry both the SpMas-bn5 and SpMas-bn3 genes. This represents one-fourth of the progeny population.

20 Thus, in cross (1) and (2), kanamycin-resistant, chlorsulfuron resistant and doubly-resistant progeny are expected. However, in cross (3), only kanamycin-resistant and chlorsulfuron resistant progeny are expected, with the doubly-resistant zygotes being killed by reconstitution of barnase activity.

Example 4

Example 4 describes tobacco lines expressing an amino-terminal barnase partial peptide and a carboxy-terminal barnase partial peptide under control of a promoter expressed in seed coats.

30 As described in example 1, chimeric genes are prepared in which bn5 and bn3 coding sequences are each operably linked to a seed coat promoter isolated from watermelon, and known as pWM403. A 2 kbp fragment of the region preceeding the start

of transcription of the WM403 gene is used for each chimeric gene. The individual bn5 and bn3 chimeric genes are cloned into plant binary vectors pWTT2200 and pNG5185 respectively, as described in example 3 above. Three independent transgenic individuals from each class are selected as high expressers, and three transgenic individuals of each control transformant class (vector only) are also selected. Crosses are made between 20 1) pWM403-bn5 transgenic plants and pNG5185 transgenic plants, 20 2) pWM403-bn3 transgenic plants and pWTT2200 transgenic plants, and 3) pW M403-bn5 and pWM403-bn3 transgenic plants. Progeny plants resistant to both chlorsulfuron and kanamycin are selected and grown to maturity for evaluation of seed and seed coat
10 development.

Example 5

Example 5 describes tobacco lines expressing an amino-terminal barnase partial peptide and a carboxy-terminal barnase partial peptide under control of two
15 different promoters expressed in seed coats.

As described in example 1, chimeric genes are prepared in which bn5 and bn3 coding sequences are each operably linked to a seed coat promoter isolated from tobacco, and known as pT218 (Fobert *et al.*, *The Plant Journal* 6:567-77 (1994)). A 2 kbp fragment of the T218 promoter is used for each chimeric gene. As described in
20 example 4, bn5 and bn3 chimeric genes are cloned into the plant binary vectors pWTT2200 and pNG5185 respectively. High expressing transgenic individuals are identified as described in example 4. Crosses are made between 1) pT218-bn5 transgenic plants and pNG5185 transgenic plants, 2) pT218-bn3 transgenic plants and pWTT2200 transgenic plants, 3) pT218-bn5 and pWM403-bn3 transgenic plants, and 4) pWM403-bn5
25 and pT218-bn3 transgenic plants. Progeny plants resistant to both chlorsulfuron and kanamycin are selected and grown to maturity for evaluation of seed and seed coat development.

Example 6

Example 6 describes tobacco lines expressing an amino-terminal barnase partial peptide and a carboxy-terminal barnase partial peptide under control of a promoter expressed in tapetal cells.

5 As described in example 1, chimeric genes are prepared in which bn5 and bn3 coding sequences are each operably linked to a tapetal-specific promoter isolated from tobacco, and known as pTA29 (Mariani *et al.*, *Nature* 347:737-41, (1990)). As described in example 4, bn5 and bn3 chimeric genes are cloned into the plant binary vectors pWTT2200 and pNG5185, respectively. High expressing transgenic individuals are
10 identified as described in example 4. Crosses are made between 1) pTA29-bn5 transgenic plants and pNG5185 transgenic plants, 2) pTA29-bn3 transgenic plants and pWTT2200 transgenic plants, and 3) pTA29-bn5 and pTA29-bn3 transgenic plants. Progeny plants resistant to both chlorsulfuron and kanamycin are selected and grown to maturity for evaluation of pollen development and male fertility.

15

Example 7

Example 7 describes development of two-component system based on colicin E7 nuclease function.

Gene sequences are known for four colicins that share extensive sequence
20 homology over the latter 210 amino acids of their sequence, with the amino terminal portion of the colicins being very different. A region of approximately 15,000 daltons of the carboxy terminal end of the colicins comprises a non-specific nuclease function known to be involved in the cell death of cells into which the nuclease is targeted via the amino terminal segment. Alignment of these sequences reveals a region of approximately 30
25 amino acids located 65 - 35 amino acids from the carboxy terminus which is highly variable. Within this region of colicin is a methionine residue 55 amino acid residues from the carboxy terminus of the protein.

Based on the known sequence of colicin E7, the 5' coding sequence is created, through polymerase chain reaction, by incorporating a methionine codon in place
30 of the leucine codon located at position 135 residues from the carboxy terminus, with a stop codon inserted in place of the methionine codon at residue 55 from the carboxy terminus. The 3' coding sequence is created, through polymerase chain reaction, using the

methionine codon at residue 55 from the carboxy terminus as the initiation codon and using the normal stop codon of the colicin E7 message. Other two-component candidates are made in a similar fashion but replacing 1) the threonine at position 48 residues from the carboxy terminus with a stop codon for the 5' coding sequence and with a methionine codon for the 3' coding sequence, or 2) the valine at position 43 residues from the carboxy terminus with a stop codon for the 5' coding sequence and with a methionine codon for the 3' coding sequence. Similar amino acid replacements are made in the same region to produce a range of other candidate two-component systems.

Each pair of coding sequences is cloned, as described in example 1, into a vector with the SpMas promoter to create genes that are constitutively expressed in plant cells. The pair of candidate genes is then introduced biolistically into plant leaf disks either separately or in combination as shown in example 2.

Example 8

Example 8 describes a two-component system for the reconstitution of a lethal function in plant cells.

Example 8A: Example 8A describes the subcloning of two partial barnase genes (bn3 and bn5) using the 35S promoter, and the subcloning of a barstar gene using a enhanced 35S promoter.

The partial bn3 and bn5 genes operably linked to the 35S promoter were subcloned in the following manner. Plasmids pER4013 (SpMAS-bn5, encoding the barnase gene bn5) and pER4022 (SpMAS-bn3, encoding the barnase gene bn3) were digested with NcoI and XbaI, and the fragments corresponding to the bn5 and bn3 coding regions were gel purified. Plasmid pEL5051, which contains a 35S-Gus synthetic gene, was digested with NcoI and XbaI, which excised the GUS coding region. The remaining NcoI/XbaI fragment from pEL5051, containing the 35S promoter, was then gel purified. The bn3 and bn5 fragments were then each separately cloned into this NcoI/XbaI fragment of pEL5051 to make pEL5152 and pEL5161, which respectively encode bn3 and bn5, each linked to the 35S promoter.

The barstar gene operably linked to the enhanced 35S promoter was subcloned in the following manner. The complete barstar coding sequence from *Bacillus*

amyloliquefaciens is available from GenBank under Accession No. X15545 (Hartley, J. Mol. Biol. 202:913-915 (1988)). First, a complete coding sequence of barstar was obtained. To produce a coding sequence that included the complete functional barstar, PCR primers corresponding to the ends of the barstar coding sequence were made. These primers contained additional restriction sites for BspHI at the 5' end and XbaI at the 3' end. The primers were used for PCR amplifications using *Bacillus amyloliquefaciens* genomic DNA with TAQ DNA polymerase according to the manufacturer's recommendations. *Bacillus amyloliquefaciens* strain ATCC No. 23842 chromosomal DNA was isolated according to standard methods. The PCR fragments were digested with BspHI and XbaI and the fragment with the barstar coding sequence was gel purified and cloned into pUC120 digested with NcoI and XbaI.

At least two plasmids were identified by restriction digest as having the correct size insert band. These plasmids were sequenced and one plasmid with the correct barstar sequence was designated pNG5011. Plasmid pNG5011 was used as a source of DNA for a second round of PCR amplification as described above, except that Vent DNA polymerase was used. The resulting fragments were gel purified and cloned into EcoRV-digested pBluescript plasmid. At least two plasmids identified by restriction digest as having the correct size fragment were sequenced and the correct barstar sequence was confirmed for at least one of these clones. This plasmid was designated pBH4004. Plasmid pBH4004 was digested with BspHI and XbaI and the fragment corresponding to barstar was gel purified.

Second, the enhanced 35S promoter was obtained. Plasmid pKL3049 contains a synthetic gene comprised of a 35S promoter with two copies of an 35S enhancer region (this promoter is designated e35S or enhanced 35S) attached at an NcoI restriction site to a chitinase coding sequence, ChiA, which is joined to a NOS 3' region at a XbaI restriction site. Plasmid pKL3049 was digested with NcoI and XbaI and the fragment containing the e35S promoter was gel purified. This gel purified fragments containing the e35S promoter was ligated to the gel purified barstar fragment described above, and the resulting plasmid was designated pSG5351, which constitutes a e35S-barstar synthetic gene.

Example 8B: Example 8B describes a biolistics assay for the reconstitution of a lethal function in plant cells. This example shows that the lethal function is due to the RNase activity of a reconstituted barnase. This reconstitution was demonstrated by the specific reduction of this lethal function with co-expression of barstar, the specific inhibitor of the RNase activity of barnase.

Reconstitution of cell lethality was assayed by bombarding plant leaves with a mixture of pEL5152 and pEL5161 plasmid DNA along with DNA of the plasmid pJJ3792, which comprises a 35S-LUC chimeric gene. To demonstrate that this reconstituted activity is responsive to the inhibition of the RNase activity of barnase, plant leaves were bombarded with a mixture of pEL5152, pEL5161 and pSG5351, along with pJJ3792. As controls, pEL5152, pEL5161, and pSG5351 were delivered biolistically, separately, with pJJ3792.

The plasmid DNAs were prepared as double stranded circular molecules purified by two rounds of CsCl density gradient centrifugation. After determining the DNA concentration by spectrophotometer, the concentration of each plasmid was adjusted to 400 mg/ml in 10 mM tris 1 mM EDTA, pH 8.0. The plasmids were mixed according to standard methods as described in example 2, except that 40 μ L of each DNA mixture was mixed with 20 μ L of tungsten particles, 20 μ L of 100 mM spermidine, and 50 μ L of 2.5 M CaCl₂. After centrifugation, the particles were suspended in 50 μ L of 70% ethanol. The 40 μ L DNA mixture contained 4 μ L of pJJ3792 and 12 μ L of pEL5152, pEL5161, or pSG5351 either separately or together. A CsCl purified filler DNA was used to bring the volume for each sample to 40 μ L.

Bombardment was performed as described in example 2, except that tobacco leaf disk are used and the helium pressure was 150 psi. Luciferase assays were performed as described in example 2 except that plant leaf extracts were prepared in 200 μ L of Cell Lysis Buffer (Promega), the samples were centrifuged, and then 20 μ L of the supernatant was diluted to 100 μ L with Cell Lysis Buffer. The assay used 40 μ L of assay solution and 5 μ L of diluted plant extract. Typical luciferase assay results are shown in Table 5 and are reported as the average cpm for 10 leaf disk per treatment.

The combination of 35S-bn5 and 35S-bn3 resulted in an 86% reduction in luciferase activity as compared with the average of the three controls. The addition of e35S-barstar to 35S-bn3 and 35S-bn5 resulted in a restoration of luciferase activity to 48%

of the average of the controls. This result indicates that the cell lethal function reconstituted by the expression of bn5 and bn3 in the same cell is the RNase activity of barnase.

Table 5. Luciferase activity recorded as the cpm per tobacco leaf disk and as the average cpm for 10 tobacco leaf disks. Values are (measured cpm minus background) x .001.

Gene construct	bn3	bn5	barstar	bn3 + bn5	bn3 + bn5 + barstar
shot 1	166	288	442	6	89
shot 2	125	336	79	88	133
shot 3	649	1,252	534	84	143
shot 4	793	2,577	1,352	136	100
shot 5	321	1,714	1,229	208	165
shot 6	124	1,170	1,562	174	959
shot 7	1,394	738	2,068	138	1,265
shot 8	1,101	1,562	1,432	297	1,355
shot 9	1,244	1,428	1,307	247	977
shot 10	649	5,627	512	155	219
average	657	1,669	1,052	153	540

Example 9

Example 9 describes improvement in function of the two-component system through site-specific mutagenesis.

Example 9A: Example 9A describes construction of chimeric genes that encode mutagenized peptides for enhanced stability.

For the bn5 gene, specific nucleotide changes were introduced so that the amino acid sequence was changed from

MAQVINTFDGVADYLTQYHKLPDNYITKSEAQALGW to

MAQVINTFDGVADYLIRYHKLPDNYITKSEAQALGW. The glutamine residue at

position 16 of bn5 (position 15 of mature barnase protein) was replaced by an isoleucine residue, and the arginine residue at position 17 of bn5 (position 16 of mature barnase protein) was replaced by an arginine residue (changes underlined). For the bn3 sequence, specific nucleotide changes were introduced so that the amino acid sequence was changed from MASKGNLADVAPGKSIGGDIFSNREGKLPKGSGRTWREADINYTSGFRNS DRILYSSDWLIYKTTDHYQTFTKIR to MASKGNLADVAPGKSIGGDIFSNRESKLPKGSGRTWREADINYTSGFRNSDRILYSS DWLIYKTTDHYQTFTIR. The glycine residue at position 30 of bn3 (position 65 of mature barnase protein) was replaced by a serine residue, and the lysine residue at position 73 of bn3 (position 108 of mature barnase protein) was replaced by an arginine residue (changes underlined).

The nucleotide changes were introduced by PCR, using the same general methods of example 1. To create the modified bn5 sequence, two PCR reactions were performed, using a barnase coding sequence-containing plasmid as template, one with primers NC207 and NC225, the other with NC224 and NC143.

NC207: 5' GGCCATGGCACAGGTTATCAACACGTTTGACGGGGTTGC 3'

NC225: 5' AGGAAGCTTATGATATCTGATAAGATAATCCGCAACCCCG 3'

NC224: 5' CATAAGCTTCCTGATAATTACATTACAAAATC 3'

NC143: 5' CGTCTAGATTACCAGCCGAGGGCTTGTGCTTC 3'

The resulting DNA fragments were gel purified and then mixed together prior to performing a PCR reaction with primer pair NC207 and NC143. The resulting fragment was digested with HindIII to confirm the fragment identity and then digested with NcoI and XbaI prior to cloning into pUC120. The resulting plasmid, comprising the full, modified coding sequence of bn5 (bn5-2), was designated pAR4554. The cloned fragment was sequenced.

To create a modified bn3 sequence, two PCR reactions were performed, using a barnase coding sequence-containing plasmid as template, one with primers NC144 and NC221, and one with NC222 and NC223.

NC144: 5' GGCCATGGCATCAAAAGGGAACCTTGCAGA 3'

NC221: 5' CCATGTGCGGCCGCTTTTGCTCGGGAGTTTGCCTTC 3'

NC222: 5' AAAAGCGGCCGCACATGGCGTGAAGCGGATATTAA CTATGTATCAGGCTTCAG 3'

NC223: 5' CGTCTAGAGTTATCTGATCCTTGTAAGGTCTG 3'

The resulting DNA fragments were gel purified and then mixed together prior to performing a PCR reaction with primer pair NC144 and NC223. The resulting fragment was digested with NotI to confirm the fragment identity and then digested with NcoI and XbaI prior to cloning into pUC120. The resulting plasmid, comprising the full, modified coding sequence of bn3 (bn3-2), was designated pAR4561. The cloned fragment was sequenced.

In order to create chimeric genes that express the modified bn5 and modified bn3 peptides constitutively in plants, plasmids pAR4554 and pAR4561 were digested with NcoI and XbaI, the suitable fragments were gel purified, and each was inserted into plasmid pEL5051, with the bn5-2 and bn3-2 coding sequences replacing the coding sequence of the beta-glucuronidase (uidA) gene removed by NcoI-XbaI digestion and gel purification of the resulting large fragment. The resulting chimeric genes have each partial coding sequence operably linked to the CaMV 35S promoter and to the 3' polyadenylation region of the octopine synthase gene. The size of the inserted fragments was verified by agarose gel electrophoresis. The plasmid containing the chimeric bn5-2 gene was designated pEL5061, and the plasmid containing the chimeric bn3-2 gene was designated pEL5071.

Example 9B: Example 9B describes biolistics assays to determine activity of the two modified peptides compared with the unmodified peptides in plant cells.

Reconstitution of ribonuclease activity is assayed as described in example 8, by the biolistics delivery of the two partial genes together in comparison with the 2 partial genes individually. This is done in a single experiment, with leaf tissue of a young tobacco plant as the target for DNA delivery. The data from a typical experiment are shown in Table 6. When the modified barnase fragments were expressed in the same cell, the luciferase activity was reduced to 19% of the average of the four controls. When the unmodified barnase fragments were expressed in the same cell, the luciferase activity was reduced to less than 56% of the average of the four controls.

Table 6. Luciferase activity recorded as cpm per tobacco leaf disk and as the average for 11 leaf disks per treatment. Data is reported as (measured cpm minus background) x .001.

Gene construct	bn5-2	bn3-2	bn5	bn3	bn5-2+bn3-2	bn5 + bn3
shot 1	120	123	79	214	32	76
shot 2	289	115	124	68	53	75
shot 3	78	107	217	115	44	111
shot 4	221	341	308	261	139	134
shot 5	583	162	156	543	52	218
shot 6	232	401	958	461	32	143
shot 7	1,265	970	1,079	311	59	191
shot 8	769	844	1,202	342	76	272
shot 9	127	145	832	402	100	140
shot 10	205	161	742	1,912	60	334
shot 11	144	232	291	974	65	422
average	367	327	544	509	65	193

Reconstitution of ribonuclease activity was also assayed with leaf tissue of a young pepper plant as the target for DNA delivery. The data from one experiment are shown in Table 7. When the modified barnase fragments were expressed in the same cell, the luciferase activity was reduced to 9% of the average of the four controls. When the unmodified barnase fragments were expressed in the same cell, the luciferase activity was reduced to 60% of the average of the four controls.

Table 7. Luciferase activity recorded as cpm minus background per pepper leaf disk and as the average for 8 leaf disks per treatment. Data is reported as (measured cpm minus background) x .001.

Gene construct	bn5-2	bn3-2	bn5	bn3	bn5-2 + bn3-2	bn5 + bn3
shot 1	3	6	23	41	8	20
shot 2	-2	24	275	16	5	16
shot 3	34	87	44	20	11	69
shot 4	440	95	217	156	10	69
shot 5	61	130	146	32	4	6
shot 6	16	83	42	26	10	59
shot 7	47	122	29	7	5	199
shot 8	325	77	348	8	6	10
average	115	78	140	38	8	56

Example 9C: Example 9C describes biolistics assays to determine the

relative activity of the 2 modified peptides compared with the unmodified peptides in plant cells.

A dilution experiment was performed, with decreasing amounts of the 2 modified partial genes used for DNA delivery. This was done in a single experiment, with leaf tissue of a young pepper plant as the target for DNA delivery as described in example 8. The data from a typical experiment are shown in Table 8. The modified barnase fragments bn5-2 and 3-2, when used together at 2, 6 and 18 μ L, have 60%, 17% and 9% of the luciferase activity of the average value of the four controls. The unmodified barnase fragments bn5 and bn3, when used together at 18 μ L have 60% of the luciferase activity of the average value of the four controls. Approximately 10% of the amount of the modified partial genes gives equal reduction in LUC activity compared with the standard amounts of the 2 unmodified partial genes. Similar data were obtained when this experiment was repeated.

Table 8. Luciferase activity recorded as cpm per pepper leaf disk and as the average for 8 leaf disks per treatment. Data is reported as (measured cpm minus background) x .001.

Gene construct	bn5-2	bn3-2	bn5	bn3	2 μ L bn5-2 +bn3-2	6 μ L bn5-2 +bn3-2	18 μ L bn5-2 +bn3-2	18 μ L bn5-2 +bn3-2
shot 1	3	6	23	41	88	5	8	20
shot 2	-2	24	275	16	19	10	5	16
shot 3	34	87	44	20	46	18	11	69
shot 4	440	95	217	156	12	45	10	69
shot 4	61	130	146	32	46	29	4	6
shot 6	16	83	42	26	194	17	18	59
shot 7	47	122	29	7	21	5	5	199
shot 8	325	77	348	8	1	2	6	10
average	115	78	140	38	55	16	8	56

Experiment 9D: Experiment 9D describes biolistics assays to determine activity of the 2 modified peptides compared with the unmodified peptides in pea pod tissue.

Reconstitution of ribonuclease activity in pea pod tissue was assayed as described in example 8, by the biolistics delivery of the 2 partial genes together in comparison with a luciferase with filler DNA only control. This was done in a single experiment, with tissue from the inner surface of immature pea pods as the target for DNA delivery. The data from a typical experiment are shown in Table 9. When the modified barnase fragments are expressed in the same cell, the luciferase activity is reduced to 2% of the Luc controls.

Table 9. Luciferase activity recorded as cpm per pea pod disk and as the average for 12 disks per treatment. Data is reported as (measured cpm minus background) x .001.

Gene construct	LUC with filler DNA	LUC with bn5-2 and bn3-2
shot 1	3,987	643
shot 2	38,575	57
shot 3	16,964	162
shot 4	13,852	51
shot 5	19,809	98
shot 6	7,964	8
shot 7	15,988	81
shot 8	15,495	2,060
shot 4	9,635	79
shot 10	20,903	124
shot 7	32,932	512
shot 12	17,476	748
average	17,798	385

Example 9E: Example 9E describes biolistics assays to determine activity of the two modified peptides compared with the unmodified peptides in pea seed coat tissue.

Reconstitution of ribonuclease activity in pea seed coat tissue was assayed as described in example 8, by the biolistics delivery of the two partial genes together in comparison with a luciferase with filler DNA only control. This was done in a single experiment, with tissue from immature pea seeds (less than 0.9 cm in diameter) as the target for DNA delivery. The data from one experiment are shown in Table 10. When the modified barnase fragments were expressed in the same cell, the luciferase activity was reduced to 2% of the Luc controls.

Table 10. Luciferase activity recorded as cpm per pea seed coat and as the average for 6 disks per treatment. Data is reported as (measured cpm minus background) x .001.

Gene construct	LUC with filler DNA	LUC with bn5-2+bn3-2
shot 1	29,675	176
shot 2	35,205	543
shot 3	8,190	4
shot 4	4,646	278
shot 5	1,477	135
shot 6	980	227
average	13,362	227

Example 10

Example 10 describes that when the two partial genes are introduced into tobacco cells by *Agrobacterium*, cell lethality results.

Plasmids carrying the bn5 and bn3 chimeric genes, e.g., as described in example 9A, are digested to liberate the chimeric genes themselves. The chimeric genes are each inserted at an appropriate restriction site in a T-DNA vector.

In addition, a control lethality gene is used which has a barnase coding sequence disrupted by an intron to prevent bacterial expression of barnase activity. For instance, the st-1s ivs2 intron used by Vancanneyt *et al.*, *Mol. Gen. Genet.* 220:245-50 (1990) is inserted into the valine codon at position 36 of the mature barnase protein (position 37 of the barnase gene used here, due to the addition of a methionine residue prior to the alanine residue of the mature barnase protein). A chimeric gene is constructed using the barnase coding sequence with the intron operably linked to the CaMV 35S promoter and to the octopine synthase 3' untranslated region at the 3' end. An appropriate T-DNA vector is prepared from this construct.

Young tobacco leaf plants are used for *Agrobacterium*-mediated DNA delivery, according to standard techniques, of 1) 35S-bn5 by itself, 2) 35S-bn3 by itself, 3) 35S-bn5/35S-bn3 together, or 4) 35S-barnaseINT. An *Agrobacterium* colony containing the appropriate plasmid, each from a fresh plate is used to inoculate 5 ml of LB

containing 10 μ g per ml tetracycline. These cultures are grown at 28°C for 48 hours. One ml of each culture is then transferred into separate flasks with 50 ml of LB containing 20 μ M acetosyringone and 10 μ g per ml of tetracycline. These cultures are grown at 28°C for 16 hours. The cells are then spun down in a table top centrifuge for 30 min. and the cells are suspended in 50 ml of MS salts with 3% sucrose, 0.5 mM MES pH 5.6 and 10 μ M acetosyringone. The OD at 600 nm is adjusted to 1 to 1.5. Cells are then left at room temperature for up to 3 hours before injection into leaves.

Tobacco leaves 7 to 10 cm in length are nicked only on the underside and *Agrobacterium* bacteria is infiltrated into the leaf by filling a 1 ml syringe with *Agrobacterium* and placing the syringe tip (with no needle) tight against the nick. Pressure is applied to the syringe plunger and the sector in the leaf between the mid-rib and two lateral veins is infused with the *Agrobacterium* solution. One can monitor the introduction of the *Agrobacterium* solution by the change in color of the leaf from green to dark green when the solution is introduced.

After approximately 5 days of incubation at room temperature, cell death can be observed by chlorosis and browning followed by complete tissue collapse. Neither the bn5 nor bn3 chimeric genes individually give rise to cell death. However, when the bn5 and bn3 chimeric genes are introduced together or when intact barnaseINT is introduced, cell death is observed. Precise timing of cell death can vary.

Example 11

Example 11 describes use of a repressor/activator fusion protein to induce expression of barnase in tapetal cells.

The method is diagramed in Figure 1. In the Maintainer Field sub-lines A₁ and A₂, which are male fertile, are crossed to yield line A which is male sterile. Subline A₁ has a dominant male sterile gene (Ms) with an artificial promoter consisting of one or more tet operators and a TATA-box. In this condition, the male sterile gene is not transcribed and subline A₁ is male fertile. Subline A₂ has a tapetal-specific promoter driving the expression of a chimeric transcriptional activator. This transcriptional activator is made by fusing the tet repressor, which recognizes the tet operator, to a eukaryotic activation domain, the virion protein 16 (VP16) activation domain from *Herpes simplex* virus. This tet repressor/VP16 activator fusion (which is abbreviated in the diagram as

"Act") has been shown by Weinmann et al. (1994), *supra*, to activate transcription in plants from a minimal promoter plus 7 tet operators. Sublines A₁ and A₂ are crossed to produce line A, which is male sterile since it contains both the transcriptional activator (Act), which is expressed specifically in the tapetum, and the tet operator-Ms gene. The transcriptional activator binds to the tet operator inducing expression of the male sterile gene specifically in the tapetum. Tapetal-specific expression of Ms genes such as ribonucleases (e.g., Barnase), has been shown to produce male sterility. In the hybrid seed production field, line A, which is male sterile, can then be crossed to any line B, to produce hybrid seeds.

10 In many crops it is advantageous for the hybrids produced to be male fertile. This is also illustrated in Figure 1, which shows the use of the cre/lox system to create two alternative alleles at one locus, one allele (A₁) consisting of the tet operator-Ms gene and the other allele (A₂) consisting of the tet repressor/VP16 activator driven off a tapetal-specific promoter. The initial transformant has a tet operator-Ms gene inserted in
15 opposite orientation between a tapetal-specific promoter and the tet repressor/VP16 activator. Lox sites are placed in the same orientation on both sides of the tet operator-Ms insert. When made homozygous, this is used as line A₁. The tet repressor/activator in this line is silent since an insert is present in between the tapetal-specific promoter and the tet repressor/activator. The Ms gene is also silent, but is activated upon crossing to a line
20 carrying a tet repressor/activator. Line A₂ is created by crossing line A₁ to a line carrying cre recombinase (from bacteriophage P1). Cre recombinase excises the tet operator-Ms gene, allowing the tet repressor/activator to be expressed in the tapetum. When made homozygous, this is used as line A₂.

25

Example 12

Example 12 describes use of the AVR9 elicitor polypeptide from *Cladosporium fulvum* and the corresponding resistance gene, Cf9 from *Lycopersicon esculentum* to specifically kill tapetal cells.

30 A method to produce hybrid seed using this embodiment is diagramed in Figure 2. In the Maintainer Field sub-lines A₁ and A₂, which are male fertile, are crossed to yield line A which is male sterile. In subline A₁ the *Cladosporium fulvum* Avr9 avirulence gene is expressed off of a tapetal-specific promoter (p127a, described in U.S.

Patent No. 5,254,801). The AVR9 polypeptide is fused to a signal peptide from the tobacco Pr1a protein, as described in Hammond-Kosack *et al.* (1994). In subline A₂ the tomato Cf9 gene (the corresponding tomato resistance gene) is expressed off of a second tapetal-specific promoter ("TA29" in this illustration). Both sublines A₁ and A₂ are male
5 fertile since the AVR9 and Cf9 polypeptides, when expressed separately, do not confer cell-death. However, when sublines A₁ and A₂ are crossed together to produce line A, a hypersensitive response (HR) is initiated in the tapetum resulting in cell death.

Hammond-Kosack *et al.* (1994) and Jones *et al.* (1994) have shown that cells expressing both AVR9 and Cf9 become necrotic and that Cf9 expression is cell-autonomous. Tapetal
10 cell-death should therefore confer male-sterility without adversely affecting other organs. The use of two distinct tapetal-specific promoters to express Cf9 and Avr9 greatly minimizes the risk that some expression might occur outside of the tapetum resulting in the death of that tissue. In the hybrid seed production field, line A, which is male sterile, can then be crossed to any line B, to produce hybrid seeds.

15 As in the previous example, the cre/lox system is used to create two alternative alleles at one locus, one allele (A₁) carrying the p127a-Avr9 gene and the other allele (A₂) carrying the TA29-Cf9 gene. The initial transformant has a p127a-Avr9 gene inserted in opposite orientation between a tapetal-specific promoter and Cf9. Lox sites are placed in the same orientation on both sides of the p127a-Avr9 insert. When made
20 homozygous, this is used as line A₁. The TA29-Cf9 gene in this line is silent since an insert is present between the tapetal-specific promoter and the Cf9 gene. Only the p127a-Avr9 gene will be expressed in this line. Line A₂ is created by crossing line A₁ to a line carrying cre recombinase (from bacteriophage P1). Cre recombinase would excise the p127a-Avr9 gene, allowing the TA29-Cf9 gene to be expressed. When made
25 homozygous, this is used as line A₂.

Example 13

Example 13 describes use of the cre-lox system to insert two functional expression cassettes into a lox site previously introduced into a plant genome. The method
30 uses a combination of mutant lox sites as described by Albert *et al.* *Plant J.* 7:649-659 (1995) to increase efficiency of the insertion event as compared to excision.

A mutant lox site (lox₆₆, as described by Albert *et al.*) is introduced into a desired plant genome using a recombinant expression cassette having a CaMV35S promoter linked to a structural gene encoding cre. The lox₆₆ site is placed between the structural gene and the promoter. Protoplasts from this plant are then transformed with a plasmid carrying a second mutant site (lox₇₁) linked to a selectable marker such as hygromycin phosphotransferase (*hpt*) plus a first functional expression cassette (*e.g.*, AVR9 under control of a tapetal-specific promoter). Insertion of the *hpt* at the lox site yields a 35S-lox_{wt}-*hpt*, which provides a selectable marker (hygromycin resistance). The wild-type lox site is reconstructed from the cross-over event between the two mutant sites.

10 Farther downstream, a second double mutant lox site is created, which prevents cross-over events at the insertion sites, thereby preventing excision of the inserted fragment. In addition, insertion renders the 35S-cre expression cassette non-functional, thereby preventing continued expression of the cre recombinase, which interferes with stable integration.

15 The above process is repeated using the original plant line and a second plasmid carrying a second functional expression cassette (*e.g.*, CF9 under control of a tapetal-specific promoter). After appropriate selfing, two regenerated plant lines, one homozygous for the first expression cassette and one homozygous for the second expression cassette are created. A cross between these two lines leads to heterozygous

20 plants in which the two proteins are specifically expressed in tapetal cells.

An alternate means for using insertion to create alternate alleles is to transform one plant with the 35S-lox₆₆-cre construct described above and a second plant with a construct comprising the following elements: lox₇₁-*hpt*-AVR9 under control of a tapetal-specific promoter-lox₇₁. When the two plants are crossed the *hpt*-AVR9 sequence

25 will be excised from its site of insertion and will integrate at the lox₆₆ site between the 35S promoter and the cre structural gene. Selection for hygromycin resistance allows selection of transformed cells.

As in the first method, the procedure is repeated with a second expression cassette, CF9 under control of a tapetal-specific promoter. Appropriate selfing and crosses

30 leads to heterozygous plants in which the two proteins are specifically expressed in tapetal cells.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

WHAT IS CLAIMED IS:

1. A plant cell comprising a first expression cassette comprising a first
5 non-constitutive plant promoter operably linked to a polynucleotide encoding a first
polypeptide and a second expression cassette comprising a second non-constitutive plant
promoter operably linked to a polynucleotide encoding a second polypeptide, wherein at
least the first or the second expression cassette is heterologous to the cell and the first and
second promoters have different but overlapping specificities such that the first and second
10 polypeptides are expressed in the same cell.
2. The plant cell of claim 1, wherein the first and second polypeptides
each comprise a separate subsequence of a single functional polypeptide.
- 15 3. The plant cell of claim 2, wherein the functional polypeptide is a
Barnase.
4. The plant cell of claim 1, wherein the first or the second promoter is
a tissue-specific promoter.
20
5. A plant cell comprising a first expression cassette comprising a first
plant promoter operably linked to a polynucleotide encoding a first polypeptide and a
second expression cassette comprising a second plant promoter operably linked to a
polynucleotide encoding a second polypeptide, wherein the first and second polypeptides
25 each comprise a separate subsequence of a single functional polypeptide.
6. The plant cell of claim 5, wherein the functional polypeptide is
Barnase.
- 30 7. The plant cell of claim 5, the first and second promoters have
different but overlapping specificities such that the first and second polypeptides are
expressed in the same cell.

8. A method for modifying the cellular function of a plant cell, the method comprising the steps of:

introducing into the cell a first expression cassette comprising a first non-constitutive plant promoter operably linked to a polynucleotide encoding a first polypeptide and a second expression cassette comprising a second non-constitutive plant promoter operably linked to a polynucleotide encoding a second polypeptide, wherein the first and second promoters have different but overlapping specificities such that the first and second polypeptides are expressed in the same cell.

9. The method of claim 8, wherein the first and second polypeptides each comprise a separate subsequence of a single functional polypeptide.

10. The method of claim 9, wherein the functional polypeptide is Barnase.

11. A method of modifying cellular function in a plant cell, the method comprising the steps of:

introducing into a plant cell a first expression cassette comprising a first plant promoter operably linked to a polynucleotide encoding a first non-functional polypeptide and a second expression cassette comprising a second plant promoter operably linked to a polynucleotide encoding a second non-functional polypeptide, wherein the first and second polypeptides each comprise a separate subsequence of a single functional polypeptide.

12. The method of claim 11, wherein the functional polypeptide is Barnase.

13. A method for preventing the growth of a eukaryotic cell, the method comprising the steps of:

introducing into the cell, a first expression cassette comprising a first tissue-specific promoter operably linked to a polynucleotide encoding a first polypeptide and a second expression cassette comprising a second tissue-specific promoter operably linked to a

polynucleotide encoding a second polypeptide, wherein the first and second promoters are functional in the cell and presence of the first and second polypeptides in a cell impairs cellular function.

14. A plant containing a plant cell comprising a first and a second expression cassette located at the same locus on each of two homologous chromosomes, wherein:
- the first expression cassette present on a first chromosome homolog comprises a first plant promoter operably linked to a first polynucleotide sequence encoding a first polypeptide, wherein a recombinase site is present between the first promoter and the first polynucleotide sequence;
- the second expression cassette present on a second chromosome homolog comprises the first plant promoter inoperably linked to the first polynucleotide sequence, wherein an intervening expression cassette is flanked by two recombinase sites and situated between the first promoter and the first polynucleotide sequence of the second expression cassette, the intervening expression cassette comprising a second plant promoter operably linked to a second polynucleotide sequence encoding a second polypeptide; and
- wherein the presence of the first and second polypeptides in a cell is lethal to the cell.
15. The plant of claim 14, the recombinase sites are *lox* sites.
16. The plant of claim 14, wherein the first polypeptide is a transactivator protein.
17. The plant of claim 14, wherein the second polypeptide is Barnase.
18. The plant of claim 14, wherein the first polypeptide is an avirulence gene product derived from a plant pathogen and the second polypeptide is a resistance gene product associated with the avirulence gene.

19. The plant of claim 14, wherein the first and second promoters are each functional in tapetal cells.

5 20. A method of modifying cellular function in a plant, the method comprising the steps of:
introducing into a plant a first expression cassette comprising a first plant promoter operably linked to a first polynucleotide encoding a first polypeptide, wherein a recombinase site is present between the first promoter and the first polynucleotide;
10 introducing into the plant a second expression cassette comprising the first plant promoter inoperably linked to a polynucleotide encoding the first polypeptide, wherein an intervening expression cassette is flanked by recombinase sites and situated between the first promoter and the first polypeptide of the second expression cassette, the intervening expression cassette comprising a plant promoter operably linked to a polynucleotide encoding a second polypeptide; and
15 wherein the presence of the first and second polypeptides in a cell is lethal to the cell.

21. The method of claim 20, wherein the recombinase sites are *lox* sites.

20 22. The method of claim 20, wherein the second polypeptide is Barnase.

23. The method of claim 20, wherein the first polypeptide is an avirulence gene product derived from a plant pathogen and the second polypeptide is a resistance gene product associated with the avirulence gene.

25 24. A method of modifying cellular function in a plant, the method comprising the steps of:

providing plant from a first plant line having integrated into its genome a first expression cassette located between recombinase sites wherein the first expression
30 cassette is not lethal to the cell;

providing plant from a second plant line having integrated into its genome a second expression cassette located between recombinase sites wherein the second expression cassette is not lethal to the cell;

5 wherein the recombinase sites are at the same locus on each of two homologous chromosomes and the presence of the first and second expression cassettes in a plant cell is lethal to the cell; and

crossing the plant from the first plant line with the the plant from the second plant line, thereby producing a hybrid plant containing a cell in which both intervening expression cassettes are functional and thereby killing the cell.

10

25. The method of claim 24, wherein the recombinase is cre and the recombinase sites are lox sites.

1/2




FIG. 1
SUBSTITUTE SHEET (RULE 26)

2/2





FIG. 2.

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/01315

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A01H 1/00, 5/00 US CL :435/410, 411, 414, 419; 800/200 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/410, 411, 414, 419; 800/200 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	WO 94/03619 A1 (ZENECA LIMITED) 17 February 1994, pages 9-11, 13, 14.	1, 8												
X	WO 91/15585 A1 (RIJKS-LANDBOUWUNIVERSITEIT WAGENINGEN) 17 October 1991, pages 1-3, especially page 3, lines 25-32.	1, 4, 8												
X	WO 93/25695 A1 (PLANT GENETIC SYSTEM N.V.) 23 December 1993, pages 5-8, 11, 13-15.	1, 4, 8, 13												
Y	ODELL et al. Seed-specific gene activation mediated by the Cre/lox site-specific recombination system. Plant Physiol. October 1994, Vol. 106, No. 2, pages 447-458, see entire document.	14-25												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"><tr><td colspan="2">* Special categories of cited documents:</td></tr><tr><td>*A* document defining the general state of the art which is not considered to be of particular relevance</td><td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*B* earlier document published on or after the international filing date</td><td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*O* document referring to an oral disclosure, use, exhibition or other means</td><td>*A* document member of the same patent family</td></tr><tr><td>*P* document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>			* Special categories of cited documents:		*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*B* earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*O* document referring to an oral disclosure, use, exhibition or other means	*A* document member of the same patent family	*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:														
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
B earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
O document referring to an oral disclosure, use, exhibition or other means	*A* document member of the same patent family													
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 18 MAY 1998		Date of mailing of the international search report 23 JUN 1998												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer  ROBERT SCHWARTZMAN Telephone No. (703) 308-0196												

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/01315

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN: MEDLINE, BIOSIS, EMBASE, CAPLUS, WPIDS, JAPIO, PATOSEP, PATOSWO
APS

Search Terms: plant, tomato, tobacco, arabidopsis, avirulence, resistance, barnase, ribonuclease, promoter

THIS PAGE BLANK (USPTO)